<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":4.216655,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpWBxAFD1wVBUNQTV4ER0sPBAJaAA1eVhdTF0EPAQ0DQExOH1VbRAgbVFJTVB1SVAcGAAJTGgAXDQo=","queueTime":0,"ttGuid":"14108666566a9f99"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full">
<meta property="description" name="description" content="AbstractAimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy.  Treatment options in patients with advanced ATTR-CM are l...">
<meta property="og:title" name="title" content="Frontiers | Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience">
<meta property="og:description" name="description" content="AbstractAimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy.  Treatment options in patients with advanced ATTR-CM are l...">
<meta name="keywords" content="Amyloid,transplant,Heart Failure,TTR = transthyretin,Outcome">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="9">
<meta name="citation_journal_title" content="Frontiers in Cardiovascular Medicine">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Cardiovasc. Med.">
<meta name="citation_issn" content="2297-055X">
<meta name="citation_doi" content="10.3389/fcvm.2022.1075806">
<meta name="citation_firstpage" content="1075806">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience">
<meta name="citation_keywords" content="Amyloid; transplant; Heart Failure; TTR = transthyretin; Outcome">
<meta name="citation_abstract" content="AbstractAimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy.  Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT).  Despite case series demonstrating comparable outcomes with CT between patients with ATTR-CM and non-amyloid cardiomyopathies, ATTR-CM is considered to be a contraindication to CT in some centres, partly due to a perceived risk of amyloid recurrence in the allograft.  We report long-term outcomes of CT in ATTR-CM at two tertiary centres.Methods and ResultsWe retrospectively evaluated ATTR-CM patients across two tertiary centres who underwent transplantation between 1990 and 2020.  Pre-transplantation characteristics were determined and outcomes were compared with a cohort of non-transplanted ATTR-CM patients.  Fourteen (12 male, 2 female) patients with ATTR-CM underwent CT including 11 with wild-type ATTR-CM and 3 with variant ATTR-CM (ATTRv).  Median age at CT was 62 years and median follow up post-CT was 66 months.  One, three, and five-year survival was 100%, 92% and 90%, respectively and the longest surviving patient was censored >19 years post CT.  No patients had recurrence of amyloid in the cardiac allograft.  Four patients died, including one with ATTRv-CM from complications of leptomeningeal amyloidosis.  Survival among the cohort of patients who underwent CT was significantly prolonged compared to UK patients with ATTR-CM generally (p<0.001) including those diagnosed under age 65 years (p=0.008) or with early stage cardiomyopathy (p<0.001). ConclusionCT is well-tolerated, restores functional capacity and improves prognosis in ATTR-CM.  The risk of amyloid recurrence in the cardiac allograft appears to be low.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2022/12/23">
<meta name="citation_publication_date" content="2023/01/19">
<meta name="citation_author" content="Razvi, Yousuf ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Porcari, Aldostefano ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Di Nora, Concetta ">
<meta name="citation_author_institution" content="Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Italy">
<meta name="citation_author" content="Patel, Rishi K. ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Ioannou, Adam ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Rauf, Muhammad U. ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Masi, Ambra ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Law, Steven ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Chacko, Liza ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Rezk, Tamer ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Ravichandran, Sriram ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Gilbertson, Janet ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Rowczenio, Dorota ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Blakeney, Iona J. ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Kaza, Nandita ">
<meta name="citation_author_institution" content="Imperial College London, United Kingdom">
<meta name="citation_author" content="Hutt, David F. ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Lachmann, Helen ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Wechalekar, Ashutosh ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Moody, William ">
<meta name="citation_author_institution" content="Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom">
<meta name="citation_author" content="Lim, Sern ">
<meta name="citation_author_institution" content="Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom">
<meta name="citation_author" content="Chue, Colin ">
<meta name="citation_author_institution" content="Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom">
<meta name="citation_author" content="Whelan, Carol ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Venneri, Lucia ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Martinez-Naharro, Ana ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Merlo, Marco ">
<meta name="citation_author_institution" content="Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy">
<meta name="citation_author" content="Sinagra, Gianfranco ">
<meta name="citation_author_institution" content="Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy">
<meta name="citation_author" content="Livi, Ugolino ">
<meta name="citation_author_institution" content="Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Italy">
<meta name="citation_author" content="Hawkins, Philip ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Fontana, Marianna ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="citation_author" content="Gillmore, Julian D. ">
<meta name="citation_author_institution" content="Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom">
<meta name="dc.identifier" content="doi:10.3389/fcvm.2022.1075806">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience","author":[{"@type":"Person","name":"Yousuf Razvi","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Aldostefano Porcari","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom","Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy"]},{"@type":"Person","name":"Concetta Di Nora","affiliation":["Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Italy"]},{"@type":"Person","name":"Rishi K. Patel","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Adam Ioannou","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Muhammad U. Rauf","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Ambra Masi","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Steven Law","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Liza Chacko","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Tamer Rezk","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Sriram Ravichandran","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Janet Gilbertson","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Dorota Rowczenio","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Iona J. Blakeney","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Nandita Kaza","affiliation":["Imperial College London, United Kingdom"]},{"@type":"Person","name":"David F. Hutt","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Helen Lachmann","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Ashutosh Wechalekar","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"William Moody","affiliation":["Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom"]},{"@type":"Person","name":"Sern Lim","affiliation":["Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom"]},{"@type":"Person","name":"Colin Chue","affiliation":["Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom"]},{"@type":"Person","name":"Carol Whelan","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Lucia Venneri","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Ana Martinez-Naharro","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Marco Merlo","affiliation":["Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy"]},{"@type":"Person","name":"Gianfranco Sinagra","affiliation":["Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy"]},{"@type":"Person","name":"Ugolino Livi","affiliation":["Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Italy"]},{"@type":"Person","name":"Philip Hawkins","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Marianna Fontana","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]},{"@type":"Person","name":"Julian D. Gillmore","affiliation":["Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom"]}],"datePublished":"2023-01-19","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2023","isPartOf":{"@type":"PublicationVolume","volumeNumber":"9","isPartOf":{"@type":"Periodical","name":"Frontiers in Cardiovascular Medicine"}}},"citation":["https://doi.org/10.3389/fcvm.2022.1075806"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="red"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/cardiovascular-medicine" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=103&amp;specialtyid=0&amp;entitytype=2&amp;entityid=755" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/cardiovascular-medicine" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/aortic-surgery-and-endovascular-repair-archive" data-event="iBarJournal-sections-a_id_3114">Aortic Surgery and Endovascular Repair Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/atherosclerosis-and-vascular-medicine" data-event="iBarJournal-sections-a_id_857">Atherosclerosis and Vascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiac-rhythmology" data-event="iBarJournal-sections-a_id_849">Cardiac Rhythmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardioneurology" data-event="iBarJournal-sections-a_id_3205">Cardioneurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-biologics-and-regenerative-medicine" data-event="iBarJournal-sections-a_id_855">Cardiovascular Biologics and Regenerative Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_802">Cardiovascular Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-genetics-and-systems-medicine" data-event="iBarJournal-sections-a_id_847">Cardiovascular Genetics and Systems Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-imaging" data-event="iBarJournal-sections-a_id_813">Cardiovascular Imaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-metabolism" data-event="iBarJournal-sections-a_id_959">Cardiovascular Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-nursing" data-event="iBarJournal-sections-a_id_3689">Cardiovascular Nursing</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_3150">Cardiovascular Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-surgery" data-event="iBarJournal-sections-a_id_816">Cardiovascular Surgery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/clinical-and-translational-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3149">Clinical and Translational Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/coronary-artery-disease" data-event="iBarJournal-sections-a_id_2001">Coronary Artery Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/general-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_850">General Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-failure-and-transplantation" data-event="iBarJournal-sections-a_id_851">Heart Failure and Transplantation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-valve-disease" data-event="iBarJournal-sections-a_id_1829">Heart Valve Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/hypertension" data-event="iBarJournal-sections-a_id_820">Hypertension</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/intensive-care-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3206">Intensive Care Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/lipids-in-cardiovascular-disease" data-event="iBarJournal-sections-a_id_2112">Lipids in Cardiovascular Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/pediatric-cardiology" data-event="iBarJournal-sections-a_id_613">Pediatric Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/precision-cardiology" data-event="iBarJournal-sections-a_id_3415">Precision Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/sex-and-gender-in-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_1832">Sex and Gender in Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/structural-interventional-cardiology" data-event="iBarJournal-sections-a_id_1325">Structural Interventional Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/thrombosis-and-haemostasis" data-event="iBarJournal-sections-a_id_2018">Thrombosis and Haemostasis</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=103&amp;specialtyid=0&amp;entitytype=2&amp;entityid=755" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/cardiovascular-medicine" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/aortic-surgery-and-endovascular-repair-archive" data-event="iBarJournal-sections-a_id_3114">Aortic Surgery and Endovascular Repair Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/atherosclerosis-and-vascular-medicine" data-event="iBarJournal-sections-a_id_857">Atherosclerosis and Vascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiac-rhythmology" data-event="iBarJournal-sections-a_id_849">Cardiac Rhythmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardioneurology" data-event="iBarJournal-sections-a_id_3205">Cardioneurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-biologics-and-regenerative-medicine" data-event="iBarJournal-sections-a_id_855">Cardiovascular Biologics and Regenerative Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_802">Cardiovascular Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-genetics-and-systems-medicine" data-event="iBarJournal-sections-a_id_847">Cardiovascular Genetics and Systems Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-imaging" data-event="iBarJournal-sections-a_id_813">Cardiovascular Imaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-metabolism" data-event="iBarJournal-sections-a_id_959">Cardiovascular Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-nursing" data-event="iBarJournal-sections-a_id_3689">Cardiovascular Nursing</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_3150">Cardiovascular Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-surgery" data-event="iBarJournal-sections-a_id_816">Cardiovascular Surgery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/clinical-and-translational-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3149">Clinical and Translational Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/coronary-artery-disease" data-event="iBarJournal-sections-a_id_2001">Coronary Artery Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/general-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_850">General Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-failure-and-transplantation" data-event="iBarJournal-sections-a_id_851">Heart Failure and Transplantation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-valve-disease" data-event="iBarJournal-sections-a_id_1829">Heart Valve Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/hypertension" data-event="iBarJournal-sections-a_id_820">Hypertension</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/intensive-care-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3206">Intensive Care Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/lipids-in-cardiovascular-disease" data-event="iBarJournal-sections-a_id_2112">Lipids in Cardiovascular Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/pediatric-cardiology" data-event="iBarJournal-sections-a_id_613">Pediatric Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/precision-cardiology" data-event="iBarJournal-sections-a_id_3415">Precision Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/sex-and-gender-in-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_1832">Sex and Gender in Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/structural-interventional-cardiology" data-event="iBarJournal-sections-a_id_1325">Structural Interventional Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/thrombosis-and-haemostasis" data-event="iBarJournal-sections-a_id_2018">Thrombosis and Haemostasis</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/cardiovascular-medicine" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Cardiovascular Medicine</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/aortic-surgery-and-endovascular-repair-archive" data-event="iBarJournal-sections-a_id_3114">Aortic Surgery and Endovascular Repair Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/atherosclerosis-and-vascular-medicine" data-event="iBarJournal-sections-a_id_857">Atherosclerosis and Vascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiac-rhythmology" data-event="iBarJournal-sections-a_id_849">Cardiac Rhythmology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardioneurology" data-event="iBarJournal-sections-a_id_3205">Cardioneurology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-biologics-and-regenerative-medicine" data-event="iBarJournal-sections-a_id_855">Cardiovascular Biologics and Regenerative Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_802">Cardiovascular Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-genetics-and-systems-medicine" data-event="iBarJournal-sections-a_id_847">Cardiovascular Genetics and Systems Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-imaging" data-event="iBarJournal-sections-a_id_813">Cardiovascular Imaging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-metabolism" data-event="iBarJournal-sections-a_id_959">Cardiovascular Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-nursing" data-event="iBarJournal-sections-a_id_3689">Cardiovascular Nursing</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-pharmacology-and-drug-discovery" data-event="iBarJournal-sections-a_id_3150">Cardiovascular Pharmacology and Drug Discovery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/cardiovascular-surgery" data-event="iBarJournal-sections-a_id_816">Cardiovascular Surgery</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/clinical-and-translational-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3149">Clinical and Translational Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/coronary-artery-disease" data-event="iBarJournal-sections-a_id_2001">Coronary Artery Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/general-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_850">General Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-failure-and-transplantation" data-event="iBarJournal-sections-a_id_851">Heart Failure and Transplantation</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/heart-valve-disease" data-event="iBarJournal-sections-a_id_1829">Heart Valve Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/hypertension" data-event="iBarJournal-sections-a_id_820">Hypertension</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/intensive-care-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_3206">Intensive Care Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/lipids-in-cardiovascular-disease" data-event="iBarJournal-sections-a_id_2112">Lipids in Cardiovascular Disease</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/pediatric-cardiology" data-event="iBarJournal-sections-a_id_613">Pediatric Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/precision-cardiology" data-event="iBarJournal-sections-a_id_3415">Precision Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/sex-and-gender-in-cardiovascular-medicine" data-event="iBarJournal-sections-a_id_1832">Sex and Gender in Cardiovascular Medicine</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/structural-interventional-cardiology" data-event="iBarJournal-sections-a_id_1325">Structural Interventional Cardiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/cardiovascular-medicine/sections/thrombosis-and-haemostasis" data-event="iBarJournal-sections-a_id_2018">Thrombosis and Haemostasis</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/cardiovascular-medicine/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=103&amp;specialtyid=0&amp;entitytype=2&amp;entityid=755" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Cardiovasc. Med.</span><span>, 19 January 2023</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. General Cardiovascular Medicine</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 9 - 2022 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fcvm.2022.1075806">https://doi.org/10.3389/fcvm.2022.1075806</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">Proceedings and Predictions in Cardiac Amyloidosis: Unsolved mysteries and challenges for the future</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 11 articles" href="https://www.frontiersin.org/research-topics/40041/proceedings-and-predictions-in-cardiac-amyloidosis-unsolved-mysteries-and-challenges-for-the-future/magazine" target="_self" data-event="customLink-linkType-a_viewAll11Articles"><span>View all 11 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/1426416" class="user-id-1426416"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1426416/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Yousuf Razvi&#x;">Yousuf Razvi</a><sup>1&#x2020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Aldostefano Porcari,&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Aldostefano Porcari<sup>1,2&#x2020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Concetta Di Nora" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Concetta Di Nora<sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1551116" class="user-id-1551116"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1551116/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Rishi K. Patel">Rishi K. Patel</a><sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Adam Ioannou" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Adam Ioannou<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2143756" class="user-id-2143756"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2143756/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Muhammad U. Rauf">Muhammad U. Rauf</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2077411" class="user-id-2077411"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2077411/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ambra Masi">Ambra Masi</a><sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Steven Law" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Steven Law<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1436772" class="user-id-1436772"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1436772/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Liza Chacko">Liza Chacko</a><sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Tamer Rezk" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Tamer Rezk<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sriram Ravichandran" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sriram Ravichandran<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Janet Gilbertson" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Janet Gilbertson<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Dorota Rowczenio" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Dorota Rowczenio<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Iona J. Blakeney" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Iona J. Blakeney<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Nandita Kaza" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Nandita Kaza<sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="David F. Hutt" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">David F. Hutt<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Helen Lachmann" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Helen Lachmann<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Ashutosh Wechalekar" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Ashutosh Wechalekar<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1222376" class="user-id-1222376"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1222376/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="William Moody">William Moody</a><sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sern Lim" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sern Lim<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Colin Chue" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Colin Chue<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Carol Whelan" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Carol Whelan<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1878223" class="user-id-1878223"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1878223/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Lucia Venneri">Lucia Venneri</a><sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Ana Martinez-Naharro" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Ana Martinez-Naharro<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Marco Merlo" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Marco Merlo<sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Gianfranco Sinagra" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Gianfranco Sinagra<sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Ugolino Livi" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Ugolino Livi<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Philip Hawkins" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Philip Hawkins<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Marianna Fontana&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Marianna Fontana<sup>1&#x2021;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/2066247" class="user-id-2066247"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2066247/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Julian D. Gillmore*&#x;">Julian D. Gillmore</a><sup>1*&#x2021;</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom</li>
<li><span><sup>2</sup></span>Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy</li>
<li><span><sup>3</sup></span>Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy</li>
<li><span><sup>4</sup></span>Imperial College London, London, United Kingdom</li>
<li><span><sup>5</sup></span>Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom</li>
</ul>
<p class="mb15"><b>Aims:</b> Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy. Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT). Despite case series demonstrating comparable outcomes with CT between patients with ATTR-CM and non-amyloid cardiomyopathies, ATTR-CM is considered to be a contraindication to CT in some centers, partly due to a perceived risk of amyloid recurrence in the allograft. We report long-term outcomes of CT in ATTR-CM at two tertiary centers.</p>
<p class="mb15"><b>Materials and methods and Results:</b> We retrospectively evaluated ATTR-CM patients across two tertiary centers who underwent transplantation between 1990 and 2020. Pre-transplantation characteristics were determined and outcomes were compared with a cohort of non-transplanted ATTR-CM patients. Fourteen (12 male, 2 female) patients with ATTR-CM underwent CT including 11 with wild-type ATTR-CM and 3 with variant ATTR-CM (ATTRv). Median age at CT was 62 years and median follow up post-CT was 66 months. One, three, and five-year survival was 100, 92, and 90%, respectively and the longest surviving patient was Censored &#x003E; 19 years post CT. No patients had recurrence of amyloid in the cardiac allograft. Four patients died, including one with ATTRv-CM from complications of leptomeningeal amyloidosis. Survival among the cohort of patients who underwent CT was significantly prolonged compared to UK patients with ATTR-CM generally (<i>p</i> &#x003C; 0.001) including those diagnosed under age 65 years (<i>p</i> = 0.008) or with early stage cardiomyopathy (<i>p</i> &#x003C; 0.001).</p>
<p class="mb0"><b>Conclusion:</b> CT is well-tolerated, restores functional capacity and improves prognosis in ATTR-CM. The risk of amyloid recurrence in the cardiac allograft appears to be low.</p>
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Systemic amyloidosis is characterized by extracellular tissue deposition of misfolded fibrillary protein. Amyloid is identified <i>ex vivo</i> by apple green birefringence when a tissue biopsy is stained with Congo red dye and viewed under cross-polarized light (<a href="#B1">1</a>). A variety of normally soluble proteins, known as &#x201C;fibril precursor proteins,&#x201D; have been identified which can misfold and self-assemble with an abnormal cross beta-sheet conformation resulting in fibrils that are proteolysis resistant (<a href="#B2">2</a>). These different &#x201C;amyloidogenic&#x201D; proteins form the basis for the classification of amyloidosis. Clinical disease occurs when amyloid deposits disrupt tissue structure and function. Whilst amyloid deposition can occur in almost any organ of the body, cardiac amyloidosis is the established leading cause of mortality in systemic amyloidosis (<a href="#B3">3</a>).</p>
<p class="mb15">Transthyretin amyloid cardiomyopathy (ATTR-CM) is the most commonly diagnosed type of cardiac amyloidosis and may be either acquired (ATTRwt-CM) or associated with inheritance of a TTR variant (ATTRv-CM) (<a href="#B2">2</a>). Historically, treatment for this inexorably progressive and ultimately fatal cardiomyopathy was supportive with meticulous fluid balance and diuretic therapy. However there have been landmark developments in disease-modifying therapy for patients with ATTR amyloidosis. Examples include TTR specific RNA interference or antisense oligonucleotide therapies such as patisiran and inotersen, TTR stabilizers such as tafamidis and acoramidis (<a href="#B4">4</a>&#x2013;<a href="#B6">6</a>), and the CRISPR/Cas9 based gene-editing therapy NTLA-2001 (<a href="#B7">7</a>). Whilst these agents show promise, to date they appear to slow or potentially halt disease progression rather than being curative. Treatments that bring about an overt clinical improvement and genuinely improve quality of life in patients with advanced ATTR-CM remain elusive.</p>
<p class="mb0">Cardiac transplantation (CT) for patients with ATTRv-CM was first reported in 2003 (<a href="#B8">8</a>). However, this was in the context of combined hepatic and CT, the dual objectives being to replace failing cardiac function and remove hepatic production of circulating variant, amyloidogenic TTR which is entirely liver-derived. Hepatic transplantation was mostly undertaken in young patients with hereditary ATTR amyloid polyneuropathy (ATTRv-PN) who typically carried the p.(Val50Met) TTR variant (<a href="#B9">9</a>). In patients with ATTRv-PN deemed suitable for liver transplantation who had concurrent amyloid cardiomyopathy, a combined hepatic and cardiac transplant would sometimes be offered (<a href="#B10">10</a>). However, the need for hepatic transplantation in patients with a predominant neuropathic ATTR amyloidosis has largely been superseded by the availability of aforementioned patisiran and inotersen, both of which have been shown to slow or halt disease progression. Consequently, younger patients with advanced ATTR-CM including ATTRwt-CM are increasingly considered for isolated CT (<a href="#B11">11</a>). There is a paucity of published data on long term outcomes in patients who receive CT for ATTR-CM (<a href="#B11">11</a>, <a href="#B12">12</a>). Allograft amyloid recurrence and accumulation in extra-cardiac organs have remained key concerns in patients with AL amyloidosis receiving CT (either isolated, or combined) (<a href="#B13">13</a>), and similar concerns regarding potential amyloid recurrence exist in ATTR-CM. Whilst patisiran and inotersen are effective at slowing ATTR amyloid production, they remain licensed only for patients with ATTRv-PN. The risk of cardiac allograft amyloid recurrence is therefore potentially greater in patients, such as those with ATTRwt-CM, who do not routinely receive TTR suppressing agents. We present multicentre outcomes with CT in 14 patients with ATTR-CM evaluated at the UK National Amyloidosis Center and the Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.</p>
<a id="h3" name="h3"></a><h2>Materials and methods</h2>
<h3 class="pt0">Patients</h3>
<p class="mb15">All patients with ATTR-CM who attended the aforementioned tertiary centers and underwent CT between November 1991 and March 2020 were retrospectively identified from the institutions&#x2019; respective databases. Patients who underwent combined liver and heart transplant were excluded. Censor date was 27th July 2022. Patients were considered for referral to a tertiary transplantation center on a case by case basis; typically patients were under aged 65 years with advanced cardiac failure attributable to ATTR-CM and had little or no significant comorbidity.</p>
<p class="mb0">Patients were managed in accordance with the Declaration of Helsinki, the Declaration of Istanbul and the International Society for Heart and Lung Transplantation Statement on Transplant Ethics. Approval for retrospective analysis and publication of their anonymized data was obtained from the Royal Free London NHS Foundation Trust Ethics Committee (ref 06/Q0501/41).</p>
<h3>Diagnosis</h3>
<p class="mb0">In each case, the diagnosis of ATTR-CM was established according to either validated non-biopsy criteria (<a href="#B14">14</a>) and/or histological confirmation of cardiac ATTR amyloid deposits with imaging evidence of amyloid cardiomyopathy by echocardiogram and/or CMR. In brief, non-biopsy diagnostic criteria for ATTR-CM consist of echocardiographic and/or CMR imaging evidence suggestive of amyloid cardiomyopathy in together with a Perugini Grade 2 or 3 Tc-DPD scan and absence of a monoclonal gammopathy. Baseline/pre-transplant characteristics were established with biochemical tests which included full blood count, renal function, liver function tests, serum NT-proBNP and high sensitivity troponin T. Serum free light chains (retrospectively from a stored serum sample in patients transplanted before 2000), immunofixation and urine immunofixation were performed in all cases. NAC ATTR Stage was calculated on the basis of NT-proBNP concentration and MDRD eGFR, as previously published (<a href="#B15">15</a>). Patients were followed routinely at NAC following CT with a full clinical evaluation, biochemical testing and echocardiography; selected cases underwent serial CMR and <sup>99m</sup>Tc-3,3-Diphosphono-1-2-Propanodicarboxylic Acid (<sup>99m</sup>Tc-DPD) scintigraphy.</p>
<h3>Bone scintigraphy</h3>
<p class="mb0">Patients underwent radionuclide scintigraphy following an intravenous injection of approximately 700 MBq of <sup>99m</sup>Tc-DPD. Whole body planar and single photon emission computed tomography with a low-dose, non-contrast CT scan (SPECT-CT) images of the heart were acquired 3 h post-injection using low energy, high resolution collimators. Cardiac uptake on all <sup>99m</sup>Tc-DPD scans was categorized according to the Perugini grading system (<a href="#B16">16</a>).</p>
<h3>Echocardiography</h3>
<p class="mb0">Image acquisition and analysis was performed by independent, experienced and appropriately accredited echocardiographers in accordance with the latest European Association of Cardiovascular Imaging guidance (<a href="#B17">17</a>).</p>
<h3>Cardiac magnetic resonance</h3>
<p class="mb0">Cardiac magnetic resonance (CMR) was performed, after 2005, on a 1.5T scanner (Magnetom Aera, Siemens Healthcare, Erlangen, Germany). Localizers and cine imaging with steady state free precession sequences (SSFP) was performed. The contrast agent used was 0.1 mmol./kg of Gadoterate meglumine. Late gadolinium enhancement (LGE) imaging was acquired with magnitude inversion recovery (MAG-IR) and phase-sensitive inversion recovery (PSIR) sequence reconstruction with SSFP read-outs. T1 mapping was performed with the modified look-locker inversion (MOLLI) recovery sequence. T1 mapping was repeated 15 min post-contrast to produce extracellular volume (ECV) maps. All CMRs were analysed by independent consultant cardiologists.</p>
<h3>Histology, proteomics, and immunohistochemistry</h3>
<p class="mb0">All biopsy samples were formalin-fixed and paraffin-embedded. Samples were stained with Congo red by the method of Putchtler, Sweat, and Levine (<a href="#B18">18</a>). Amyloid fibril type was determined by immunohistochemical staining of amyloid deposits with a range of monospecific antibodies (<a href="#B19">19</a>). Where necessary, laser microdissection and subsequent proteomic analysis definitively confirmed fibril type (<a href="#B20">20</a>).</p>
<h3>Genotyping</h3>
<p class="mb0">DNA extracted from blood was amplified by polymerase chain reaction assays and the whole coding region of the <i>TTR</i> gene was sequenced to identify any mutations.</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<h3 class="pt0">Pre-transplant characteristics</h3>
<p class="mb0">A total of fourteen cardiac allograft recipients were identified. Patient and disease-related characteristics are shown in <a href="#T1">Table 1</a>. Twelve of the fourteen recipients were male. Mean age at CT was 59 years, median time from diagnosis to CT was 22 months (IQR 13&#x2013;29 months). Nine patients had histological evidence of ATTR amyloid deposition on endomyocardial biopsy (EMB) accompanying characteristic cardiac imaging; the remaining patients fulfilled validated non-biopsy diagnostic criteria for ATTR-CM.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" name="table1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a>
<p><b>Table 1.</b> Pre-transplant patient and disease characteristics among 14 patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who underwent cardiac transplantation.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Eleven patients had ATTRwt-CM and the remaining 3 had ATTRv-CM associated with the p.(Val142Ile), p.(Gly73Ala), and p.(Ser43Asn) variants respectively. One patient was NYHA functional class IV, eleven patients were NYHA functional class III and the remaining two cases were NYHA functional class II. Median (range) NT-proBNP concentration pre-transplant was 4,202 ng/L (1,057&#x2013;8,778 ng/L), median (range) left ventricular ejection fraction (LVEF) was 39% (27&#x2013;56%) and mean (IQR) interventricular septal thickness (IVSd) was 18 mm (14&#x2013;22 mm). At diagnosis, 8 patients had NAC ATTR stage II disease, 5 had stage I disease and the NAC ATTR stage was not evaluated in the remaining patient. It is notable that patients with NAC ATTR Stage III disease were likely excluded from consideration of CT on the basis of an estimated glomerular filtration rate (eGFR) of &#x003C; 45 ml/min (<a href="#B19">19</a>).</p>
<h3>Outcomes</h3>
<h4>Survival</h4>
<p class="mb0">Post-transplant characteristics are shown in <a href="#T2">Table 2</a>. Patients were followed up for a median (range) of 66 months (21&#x2013;233 months). At Censor, 10/14 (71%) patients were alive. Post-CT 1-year survival was 100%, 3-year survival was 92%, and 5-year survival was 90%. Overall estimated post-CT survival in ATTR-CM patients by Kaplan Meier analysis was 17.7 years (95% CI: 13&#x2013;21 years). Kaplan-Meier survival curves comparing patients who were and were not transplanted, the latter group stratified by NAC ATTR disease stage or by age &#x2264; 65 years at diagnosis, are shown in <a href="#F1">Figure 1</a>. Kaplan Meier analysis showed substantially prolonged survival from diagnosis in patients who underwent CT compared to their non-transplanted counterparts regardless of age (<i>p</i> = 0.008) or disease severity (<i>p</i> &#x003C; 0.001) at the time of diagnosis.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" name="table2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a>
<p><b>Table 2.</b> Outcomes, functional, and disease characteristics in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who underwent cardiac transplantation.</p>
</div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><b>Figure 1.</b> Kaplan-Meier survival curves in 814 patients with transthyretin amyloid cardiomyopathy (ATTR-CM) stratified by NAC disease stage and compared to the cohort who underwent cardiac transplantation. Cardiac transplantation in this small cohort of selected patients was associated with a substantial prolongation of life expectancy measured from date of first diagnosis compared to patients who did not undergo cardiac transplantation (Transplant vs. NAC ATTR stage I, <i>p</i> &#x003C; 0.001; Transplant vs. NAC ATTR stage II, <i>p</i> &#x003C; 0.001; Transplant vs. NAC ATTR stage III, <i>p</i> &#x003C; 0.001) including the cohort of 71 NAC patients who were diagnosed with ATTR-CM under age 65 years (<i>p</i> = 0.008).</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">There were no reported episodes of significant post-operative bleeding. Two patients (patient 5 and 13) were successfully treated with intravenous steroids for allograft rejection in the immediate post-operative period. A further patient (Patient 4) required intravenous steroids for grade IIIA allograft rejection 8 months post CT. Two patients were successfully treated in hospital for cytomegalovirus infection during the immediate post-operative period.</p>
<p class="mb0">At the time of Censor, all but one surviving patient were NYHA functional class I. Patient 1 developed left ventricular hypertrophy 12 years following CT determined to be secondary to hypertensive heart disease. Notably, Tc-DPD scintigraphy in this patient 12 years post CT did not show evidence of cardiac allograft amyloid infiltration. The clinical course of non-surviving patients is available in further detail in <a href="#h10">Supplementary material 1</a>.</p>
<h4>Renal impairment</h4>
<p class="mb0">Post-CT renal impairment, including both acute kidney injury thought to be due to perioperative hypoperfusion, and progressive chronic kidney disease (CKD) was common and occurred in 8/14 CT recipients. Three patients required temporary post-operative hemodialysis with two recovering normal renal function, a further four were left with CKD. The final patient developed progressive CKD due to calcineurin inhibitor use 12 years after the CT which progressed to renal failure and hemodialysis dependence 19 years post-CT despite a switch from cyclosporin to sirolimus 5 years prior.</p>
<h4>Recurrence of amyloid in the cardiac allograft</h4>
<p class="mb0">All patients were assessed regularly at their respective tertiary centers following CT. All patients were assessed for graft amyloid recurrence with Tc-DPD scintigraphy and/or endomyocardial biopsies in combination with CMR imaging. No patient developed recurrent amyloid in the cardiac allograft despite the fact that 12/14 patients did not receive disease-modifying therapy for amyloidosis. Two patients (patient 2 and patient 10), both of whom had ATTRv-CM were commenced on patisiran 210 months and 6 months post-CT respectively following development of mild ATTR-PN. It is notable that patient 2 demonstrated a progressive increase in soft tissue uptake on Tc-DPD scintigraphy post-CT, despite having an allograft EMB that was persistently free from amyloid, no cardiac uptake of Tc-DPD, and no evidence of cardiac amyloidosis on CMR over 17 years after CT (<a href="#F2">Figure 2</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><b>Figure 2.</b> Anterior whole body planar <sup>99m</sup>Tc-DPD scintigraphy images in patient 2. Left and right panels were obtained seven and ten years post cardiac transplantation, respectively. Both scans are notable for the absence of cardiac uptake despite extensive soft tissue uptake which visibly increased across this 3 year interval.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb15">Here we report multicentre experience in UK and Italy of CT in ATTR-CM. To our knowledge, this is the longest period of follow-up following CT reported to date in ATTR-CM and is the only such study that is multicentre. Both short-term and long-term outcomes were excellent with survival rates comparable to patients undergoing heart transplantation for non-amyloid indications. One-year survival in transplanted ATTR-CM patients was 100%, 3-year survival 92%, and 5-year survival 90%. The International Society for Heart and Lung Transplantation (ISHLT) registry report a 1-year survival rate post-CT of 84% (<a href="#B21">21</a>). Between 2012 and 2020, the UK National Health Service transplant registry reported CT 1- and 5-year survival rates of 84 and 70% respectively. Whilst our cohort is highly selected and relatively small, Kaplan Meier analysis indicates vastly improved survival compared to unselected ATTR-CM patients, including a UK cohort of 71 un-transplanted patients diagnosed under age 65 years.</p>
<p class="mb15">Cardiac involvement is the most important determinant of mortality in systemic amyloidosis (<a href="#B3">3</a>, <a href="#B22">22</a>). For example, patients with p.(V50M)-associated ATTR-CM accompanying ATTR-PN carry a prognosis of approximately 5 years, compared to up to &#x223C;15 years in those with p.(V50M)-associated ATTR-PN alone (<a href="#B23">23</a>). The role of &#x201C;standard&#x201D; heart failure therapies including ACE inhibitors, beta blockers and sacubitril/valsartan remains uncertain in ATTR-CM. Some authors argue these aggravate hemodynamic compromise and prohibit effective diuretic therapy (<a href="#B24">24</a>). The role of SGLT2-inhibitors in ATTR-CM related heart failure is also unknown since ATTR-CM patients were excluded from relevant trials (<a href="#B25">25</a>). Novel therapeutics such as patisiran, inotersen, and tafamidis, aimed specifically at modifying the inexorably progressive clinical course of ATTR amyloidosis are now in clinical use. However, whilst these agents may be effective at slowing or halting disease progression, there are no data to suggest that they are able to restore normal cardiac function in patients with established ATTR-CM (<a href="#B4">4</a>&#x2013;<a href="#B6">6</a>). Therefore, CT remains the only therapeutic option that has the potential to restore normal cardiac function and quality of life in patients with advanced ATTR-CM.</p>
<p class="mb15">The first case of CT in amyloid cardiomyopathy was reported in 1984 in a gentleman with cardiac AL amyloidosis (<a href="#B13">13</a>, <a href="#B26">26</a>). Subsequent reports of CT in cardiac amyloidosis highlighted recurrence of amyloid in the cardiac allograft and poor outcomes in comparison to patients undergoing CT for non-amyloid indications, and resulted in amyloid cardiomyopathy being considered an absolute contraindication to CT in some centers (<a href="#B27">27</a>). However, some case series of CT in amyloid cardiomyopathy consider the condition as a single entity with no differentiation between amyloid types (<a href="#B8">8</a>, <a href="#B11">11</a>, <a href="#B12">12</a>), despite the fact that the natural history, organ tropism and prognosis of systemic AL amyloidosis indicate a more aggressive and multi-system disease phenotype than that of ATTR amyloidosis (<a href="#B15">15</a>, <a href="#B28">28</a>). This stark difference in disease natural history coupled with the absence of detectable recurrence of ATTR amyloid in the cardiac allograft of any transplanted patient despite follow up of up to 19 years warrants consideration of the ATTR-CM indication for CT independently from that of cardiac AL amyloidosis. There is strong <i>in vivo</i> and <i>in vitro</i> evidence that presence of existing amyloid in a tissue promotes ongoing local amyloid deposition (<a href="#B29">29</a>, <a href="#B30">30</a>); this phenomenon, known as &#x201C;seeding,&#x201D; was evident in patient 2 who had ongoing accumulation of soft tissue amyloid following CT but did not develop amyloid in his cardiac allograft (confirmed by allograft biopsy 17 years post-CT) which was obviously amyloid na&#x00EF;ve at the time of transplantation. One can therefore take encouragement from our cohort that ongoing, unaltered hepatic TTR synthesis does not lead to recurrent amyloid in the cardiac allograft in the short or medium term.</p>
<p class="mb15">In patients with ATTRv amyloidosis, ATTR-PN accompanying ATTR-CM is a common and important clinical manifestation (<a href="#B2">2</a>, <a href="#B4">4</a>, <a href="#B23">23</a>). Prior to the introduction of TTR suppressing and TTR stabilizing agents, liver transplantation to remove the circulating variant transthyretin, was the only available treatment for ATTR-PN. Whilst successful in patients with early-onset p.(V50M)-associated ATTRv amyloidosis who typically have ATTR-PN without ATTR-CM (<a href="#B31">31</a>), liver transplantation in patients with established ATTRv-CM did not prevent ongoing deposition of wild-type ATTR amyloid deposits on top of the existing template of variant ATTR cardiac amyloid resulting in poor outcomes (<a href="#B32">32</a>). As a result, combined liver and heart transplantation was performed in some patients with mixed ATTRv-CM and ATTRv-PN (<a href="#B33">33</a>). However, with the advent of patisiran and inotersen, liver transplantation for ATTRv amyloidosis is now rarely undertaken. A small number of the &#x003E; 130 known amyloidogenic TTR variants are particularly associated with leptomeningeal ATTR amyloid deposition including p.(Thr69Pro), p.(Leu32Pro), p.(Tyr134Cys), and p.(Gly73Ala) (<a href="#B30">30</a>, <a href="#B34">34</a>&#x2013;<a href="#B36">36</a>). Leptomeningeal ATTR amyloid deposits are composed of TTR protein which is synthesized in the choroid plexus rather than liver-derived circulating TTR protein such that patisiran and inotersen are ineffective at preventing neurological disease progression which carries a poor prognosis. Patients being considered for CT with these particular disease-causing variants need careful consideration, highlighted by the poor outcome in patient 4 in our cohort. Whilst patisiran and inotersen specifically target the liver (<a href="#B30">30</a>, <a href="#B37">37</a>), tafamidis has been shown to cross the blood brain barrier (<a href="#B37">37</a>) and could conceivably stabilize TTR in the cerebrospinal fluid and thereby slow ongoing leptomeningeal ATTR amyloid deposition although this hypothesis remains speculative at the current time (<a href="#B6">6</a>, <a href="#B38">38</a>).</p>
<p class="mb15">Extracardiac ATTR amyloidosis is well-described in the literature (<a href="#B2">2</a>). Whilst polyneuropathy, the hallmark phenotypic feature for which TTR gene silencers are licensed in ATTRv (<a href="#B4">4</a>, <a href="#B5">5</a>), is unequivocally caused by amyloid deposits it remains uncertain to what extent amyloid deposits contribute to other common organ manifestations in patients with ATTR amyloidosis such as gastrointestinal disturbance, lumbar canal stenosis and joint pains despite their almost universal presence in the relevant tissue. A recent study reported development of extra-cardiac disease manifestations following CT in patients with ATTR-CM (<a href="#B39">39</a>) which is entirely consistent with our findings in which two patients were diagnosed with amyloid polyneuropathy 210 and 6 months post CT. However, given the recent availability of TTR gene silencers that effectively halt the progression of ATTR-PN, we would argue that concerns surrounding the possible development of ATTR-PN post CT should not preclude suitable ATTR-CM patients from undergoing CT. With regular monitoring, symptoms of ATTR-PN can be detected at an early stage, and where indicated, TTR gene silencers can be introduced in a timely manner. The orthopedic symptoms which appear to be over-represented in patients with ATTR amyloidosis, such as lumbar canal stenosis and carpal tunnel syndrome, can be effectively alleviated by surgical or non-surgical intervention. Given that cardiac allograft function is typically preserved in ATTR-CM post-CT, such patients are usually able to tolerate general anesthesia from a cardiac perspective.</p>
<p class="mb15">Our study has limitations. Pre-operative invasive physiological data is not readily available due to the fact transplantation was undertaken in institutions external to the individual amyloidosis centers. Whilst multicentre, the cohort is small and highly selected and we acknowledge the limitations of statistical analyses. Additionally, since disease-modifying therapies have only been available for the past 3&#x2013;4 years, we are unable to report on outcomes with their long-term use following CT; however, the absence of amyloid recurrence within the cardiac allograft argues against the need for administration of such therapies to protect the cardiac allograft after CT in patients with ATTRwt-CM.</p>
<p class="mb0">In conclusion, CT in selected patients with ATTR-CM is a robust intervention which restores quality of life and prolongs patient survival. The risk of cardiac allograft amyloid recurrence in the short and medium term appears to be negligible. Longer term follow-up studies will be required to determine whether administration of disease-modifying therapies post-CT provides any additional clinical benefit in patients with isolated ATTR-CM. The authors advise caution when considering the suitability of patients with ATTRv-CM for CT who carry TTR mutations which are known to be associated with important leptomeningeal amyloidosis.</p>
<a id="h6" name="h6"></a><h2>Data availability statement</h2>
<p class="mb0">The anonymized raw data supporting the conclusions of this article can be made available by the authors upon reasonable request.</p>
<a id="h7" name="h7"></a><h2>Author contributions</h2>
<p class="mb0">YR and AP conceived the study, carried out data collection, analysis, and manuscript preparation. CD carried out data collection and manuscript review. RP, AI, MR, AM, StL, LC, TR, SR, JaG, DR, IB, NK, DH, HL, AW, WM, SeL, CC, CW, LV, and AM-N contributed to data analysis and manuscript review and editing. MM, GS, UL, and PH contributed with data collection, manuscript preparation, and review. MF and JuG oversaw the study design, data collection, manuscript preparation, review, and final approval. All authors contributed to the article and approved the submitted version.</p>
<a id="h17" name="h17"></a><h2>Funding</h2>
<p class="mb0">MF reports grant support from the British Heart Foundation.</p>
<a id="h8" name="h8"></a><h2>Conflict of interest</h2>
<p class="mb15">DH receives speaker fees from Akcea Therapeutics Ltd., and Alnylam UK. SeL receives support fees from Abiomed. MF has received consulting income from Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, Alnylam, Caleum, Alexion, Jennsen and her institution has received clinical trial fundings from Pfizer, Eidos, and Alnylam. JuG receives consulting fees from Alnyman, Ionis, Eidos, Intellia, Pfizer, and ATTRalus.</p>
<p class="mb0">The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h9" name="h9"></a><h2>Publisher&#x2019;s note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
<a id="h10" name="h10"></a><h2>Supplementary material</h2>
<p class="mb0">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fcvm.2022.1075806/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcvm.2022.1075806/full#supplementary-material</a></p>
<a id="h11" name="h11"></a><h2>Abbreviations</h2>
<p class="mb0">TTR, transthyretin; ATTR, transthyretin amyloid; ATTR-CM, transthyretin amyloid cardiomyopathy; CT, cardiac transplantation; ATTRv, variant/hereditary transthyretin amyloid; ATTRwt, wild type transthyretin amyloid; ATTR-PN, transthyretin amyloid polyneuropathy; Tc-DPD, Tc-3,3-Diphosphono-1-2-Propanodicarboxylic Acid; CMR, cardiac magnetic resonance; SSFP, steady state free precession; LGE, late gadolinium enhancement; MAG-IR, magnitude inversion recovery; PSIR, phase sensitive inversion recovery; MOLLI, modified look-locker inversion; ECV, extracellular volume; LVEF, left ventricular ejection fraction; IVSd, interventricular septal thickness in diastole; eGFR, estimated glomerular filtration rate; ISHLT, international society for heart and lung transplantation; LVH, left ventricular hypertrophy; CMV, cytomegalovirus.</p>
<a id="h12" name="h12"></a><h2>References</h2>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B1" id="B1"></a>1. Razvi Y, Patel R, Fontana M, Gillmore J. Cardiac amyloidosis: a review of current imaging techniques. <i>Front Cardiovasc Med.</i> (2021) 8:751293. doi: 10.3389/fcvm.2021.751293</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34957240" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fcvm.2021.751293" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+amyloidosis%3A+a+review+of+current+imaging+techniques%2E&#x0026;journal=Front+Cardiovasc+Med%2E&#x0026;author=Razvi+Y&#x0026;author=Patel+R&#x0026;author=Fontana+M&#x0026;author=Gillmore+J&#x0026;publication_year=2021&#x0026;volume=8&#x0026;issue=751293" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B2" id="B2"></a>2. Wechalekar A, Gillmore J, Hawkins P. Systemic amyloidosis. <i>Lancet.</i> (2016) 387:2641&#x2013;54. doi: 10.1016/S0140-6736(15)01274-X</p>
<p class="ReferencesCopy2"><a href="https://doi.org/10.1016/S0140-6736(15)01274-X" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Systemic+amyloidosis%2E&#x0026;journal=Lancet%2E&#x0026;author=Wechalekar+A&#x0026;author=Gillmore+J&#x0026;author=Hawkins+P&#x0026;publication_year=2016&#x0026;volume=387&#x0026;pages=2641&#x2013;54" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B3" id="B3"></a>3. Martinez-Naharro A, Hawkins P, Fontana M. Cardiac amyloidosis. <i>Clin Med J R Coll Phys Lond.</i> (2018) 18:s30&#x2013;5. doi: 10.7861/clinmedicine.18-2-s30</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29700090" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.7861/clinmedicine.18-2-s30" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+amyloidosis%2E&#x0026;journal=Clin+Med+J+R+Coll+Phys+Lond%2E&#x0026;author=Martinez-Naharro+A&#x0026;author=Hawkins+P&#x0026;author=Fontana+M&#x0026;publication_year=2018&#x0026;volume=18&#x0026;pages=s30&#x2013;5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B4" id="B4"></a>4. Adams D, Gonzalez-Duarte A, O&#x2019;Riordan W, Yang C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. <i>N Engl J Med.</i> (2018) 379:11&#x2013;21.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Patisiran%2C+an+RNAi+therapeutic%2C+for+hereditary+transthyretin+amyloidosis%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Adams+D&#x0026;author=Gonzalez-Duarte+A&#x0026;author=O&#x2019;Riordan+W&#x0026;author=Yang+C&#x0026;author=Ueda+M&#x0026;author=Kristen+AV&#x0026;publication_year=2018&#x0026;volume=379&#x0026;pages=11&#x2013;21" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B5" id="B5"></a>5. Benson M, Waddington-Cruz M, Berk J, Polydefkis M, Dyck P, Wang A, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. <i>N Engl J Med.</i> (2018) 379:22&#x2013;31.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Inotersen+treatment+for+patients+with+hereditary+transthyretin+amyloidosis%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Benson+M&#x0026;author=Waddington-Cruz+M&#x0026;author=Berk+J&#x0026;author=Polydefkis+M&#x0026;author=Dyck+P&#x0026;author=Wang+A&#x0026;publication_year=2018&#x0026;volume=379&#x0026;pages=22&#x2013;31" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B6" id="B6"></a>6. Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med.</i> (2018) 379:1007&#x2013;16.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Tafamidis+treatment+for+patients+with+transthyretin+amyloid+cardiomyopathy%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Maurer+M&#x0026;author=Schwartz+J&#x0026;author=Gundapaneni+B&#x0026;author=Elliott+P&#x0026;author=Merlini+G&#x0026;author=Waddington-Cruz+M&#x0026;publication_year=2018&#x0026;volume=379&#x0026;pages=1007&#x2013;16" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B7" id="B7"></a>7. Gillmore J, Gane E, Taubel J, Kao J, Fontana M, Maitland M, et al. CRISPR-Cas9 <i>in vivo</i> gene editing for transthyretin amyloidosis. <i>N Engl J Med.</i> (2021) 385:493&#x2013;502. doi: 10.1056/NEJMoa2107454</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34215024" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa2107454" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=CRISPR-Cas9+in+vivo+gene+editing+for+transthyretin+amyloidosis%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Gillmore+J&#x0026;author=Gane+E&#x0026;author=Taubel+J&#x0026;author=Kao+J&#x0026;author=Fontana+M&#x0026;author=Maitland+M&#x0026;publication_year=2021&#x0026;volume=385&#x0026;pages=493&#x2013;502" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B8" id="B8"></a>8. Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. <i>Heart Fail Rev.</i> (2017) 22:317&#x2013;27. doi: 10.1007/s10741-017-9601-z</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28281017" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10741-017-9601-z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Heart+transplantation+in+cardiac+amyloidosis%2E&#x0026;journal=Heart+Fail+Rev%2E&#x0026;author=Sousa+M&#x0026;author=Monohan+G&#x0026;author=Rajagopalan+N&#x0026;author=Grigorian+A&#x0026;author=Guglin+M&#x0026;publication_year=2017&#x0026;volume=22&#x0026;pages=317&#x2013;27" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B9" id="B9"></a>9. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. <i>Liver Transpl.</i> (2015) 21:282&#x2013;92. doi: 10.1002/lt.24058</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25482846" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/lt.24058" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Liver+transplantation+in+transthyretin+amyloidosis%3A+issues+and+challenges%2E&#x0026;journal=Liver+Transpl%2E&#x0026;author=Carvalho+A&#x0026;author=Rocha+A&#x0026;author=Lobato+L&#x0026;publication_year=2015&#x0026;volume=21&#x0026;pages=282&#x2013;92" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B10" id="B10"></a>10. Nardo B, Beltempo P, Bertelli R, Montalti R, Vivarelli M, Cescon M, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. <i>Transplant Proc.</i> (2004) 36:645&#x2013;7. doi: 10.1016/j.transproceed.2004.03.076</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15110620" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.transproceed.2004.03.076" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Combined+heart+and+liver+transplantation+in+four+adults+with+familial+amyloidosis%3A+experience+of+a+single+center%2E&#x0026;journal=Transplant+Proc%2E&#x0026;author=Nardo+B&#x0026;author=Beltempo+P&#x0026;author=Bertelli+R&#x0026;author=Montalti+R&#x0026;author=Vivarelli+M&#x0026;author=Cescon+M&#x0026;publication_year=2004&#x0026;volume=36&#x0026;pages=645&#x2013;7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B11" id="B11"></a>11. Davis M, Kale P, Liedtke M, Schrier S, Arai S, Wheeler M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. <i>Am J Transpl.</i> (2015) 15:650&#x2013;8.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Outcomes+after+heart+transplantation+for+amyloid+cardiomyopathy+in+the+modern+era%2E&#x0026;journal=Am+J+Transpl%2E&#x0026;author=Davis+M&#x0026;author=Kale+P&#x0026;author=Liedtke+M&#x0026;author=Schrier+S&#x0026;author=Arai+S&#x0026;author=Wheeler+M&#x0026;publication_year=2015&#x0026;volume=15&#x0026;pages=650&#x2013;8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B12" id="B12"></a>12. Kpodonu J, Massad M, Caines A, Geha A. Outcome of heart transplantation in patients with amyloid cardiomyopathy. <i>J Heart Lung Transplant.</i> (2005) 24:1763&#x2013;5. doi: 10.1016/j.healun.2004.08.025</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16297778" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.healun.2004.08.025" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Outcome+of+heart+transplantation+in+patients+with+amyloid+cardiomyopathy%2E&#x0026;journal=J+Heart+Lung+Transplant%2E&#x0026;author=Kpodonu+J&#x0026;author=Massad+M&#x0026;author=Caines+A&#x0026;author=Geha+A&#x0026;publication_year=2005&#x0026;volume=24&#x0026;pages=1763&#x2013;5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B13" id="B13"></a>13. Dubrey S, Burke M, Hawkins P, Banner N. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. <i>J Heart Lung Transpl.</i> (2004) 23:1142&#x2013;53. doi: 10.1016/j.healun.2003.08.027</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15477107" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.healun.2003.08.027" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+transplantation+for+amyloid+heart+disease%3A+the+United+Kingdom+experience%2E&#x0026;journal=J+Heart+Lung+Transpl%2E&#x0026;author=Dubrey+S&#x0026;author=Burke+M&#x0026;author=Hawkins+P&#x0026;author=Banner+N&#x0026;publication_year=2004&#x0026;volume=23&#x0026;pages=1142&#x2013;53" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B14" id="B14"></a>14. Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. <i>Circulation.</i> (2016) 133:2404&#x2013;12.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Nonbiopsy+diagnosis+of+cardiac+transthyretin+amyloidosis%2E&#x0026;journal=Circulation%2E&#x0026;author=Gillmore+J&#x0026;author=Maurer+M&#x0026;author=Falk+R&#x0026;author=Merlini+G&#x0026;author=Damy+T&#x0026;author=Dispenzieri+A&#x0026;publication_year=2016&#x0026;volume=133&#x0026;pages=2404&#x2013;12" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B15" id="B15"></a>15. Gillmore J, Damy T, Fontana M, Hutchinson M, Lachmann H, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. <i>Eur Heart J.</i> (2018) 39:2799&#x2013;806. doi: 10.1093/eurheartj/ehx589</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29048471" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehx589" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+new+staging+system+for+cardiac+transthyretin+amyloidosis%2E&#x0026;journal=Eur+Heart+J%2E&#x0026;author=Gillmore+J&#x0026;author=Damy+T&#x0026;author=Fontana+M&#x0026;author=Hutchinson+M&#x0026;author=Lachmann+H&#x0026;author=Martinez-Naharro+A&#x0026;publication_year=2018&#x0026;volume=39&#x0026;pages=2799&#x2013;806" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B16" id="B16"></a>16. Perugini E, Guidalotti P, Salvi F, Cooke R, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. <i>J Am Coll Cardiol.</i> (2005) 46:1076&#x2013;84. doi: 10.1016/j.jacc.2005.05.073</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16168294" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jacc.2005.05.073" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Noninvasive+etiologic+diagnosis+of+cardiac+amyloidosis+using+99mTc-3%2C3-diphosphono-1%2C2-propanodicarboxylic+acid+scintigraphy%2E&#x0026;journal=J+Am+Coll+Cardiol%2E&#x0026;author=Perugini+E&#x0026;author=Guidalotti+P&#x0026;author=Salvi+F&#x0026;author=Cooke+R&#x0026;author=Pettinato+C&#x0026;author=Riva+L&#x0026;publication_year=2005&#x0026;volume=46&#x0026;pages=1076&#x2013;84" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B17" id="B17"></a>17. Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. <i>J Am Soc Echocardiogr.</i> (2015) 28:1&#x2013;39.e14.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Recommendations+for+cardiac+chamber+quantification+by+echocardiography+in+adults%3A+an+update+from+the+American+society+of+echocardiography+and+the+European+association+of+cardiovascular+imaging%2E&#x0026;journal=J+Am+Soc+Echocardiogr%2E&#x0026;author=Lang+R&#x0026;author=Badano+L&#x0026;author=Mor-Avi+V&#x0026;author=Afilalo+J&#x0026;author=Armstrong+A&#x0026;author=Ernande+L&#x0026;publication_year=2015&#x0026;volume=28&#x0026;pages=1&#x2013;39.e14" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B18" id="B18"></a>18. Amyloid B, Puchtler H, Sweat F, Levine M. On the binding of congo red by amyloid. <i>J Histochem Cytochem.</i> (2017) 10:355&#x2013;64.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=On+the+binding+of+congo+red+by+amyloid%2E&#x0026;journal=J+Histochem+Cytochem%2E&#x0026;author=Amyloid+B&#x0026;author=Puchtler+H&#x0026;author=Sweat+F&#x0026;author=Levine+M&#x0026;publication_year=2017&#x0026;volume=10&#x0026;pages=355&#x2013;64" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B19" id="B19"></a>19. Rezk T, Gilbertson J, Mangione P, Rowczenio D, Rendell N, Canetti D, et al. The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. <i>J Pathol Clin Res.</i> (2019) 5:145&#x2013;53. doi: 10.1002/cjp2.126</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/30740936" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cjp2.126" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+complementary+role+of+histology+and+proteomics+for+diagnosis+and+typing+of+systemic+amyloidosis%2E&#x0026;journal=J+Pathol+Clin+Res%2E&#x0026;author=Rezk+T&#x0026;author=Gilbertson+J&#x0026;author=Mangione+P&#x0026;author=Rowczenio+D&#x0026;author=Rendell+N&#x0026;author=Canetti+D&#x0026;publication_year=2019&#x0026;volume=5&#x0026;pages=145&#x2013;53" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B20" id="B20"></a>20. Vrana J, Gamez J, Madden B, Theis J, Bergen H, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. <i>Blood.</i> (2009) 114:4957&#x2013;9. doi: 10.1182/blood-2009-07-230722</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19797517" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1182/blood-2009-07-230722" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Classification+of+amyloidosis+by+laser+microdissection+and+mass+spectrometry-based+proteomic+analysis+in+clinical+biopsy+specimens%2E&#x0026;journal=Blood%2E&#x0026;author=Vrana+J&#x0026;author=Gamez+J&#x0026;author=Madden+B&#x0026;author=Theis+J&#x0026;author=Bergen+H&#x0026;author=Dogan+A&#x0026;publication_year=2009&#x0026;volume=114&#x0026;pages=4957&#x2013;9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B21" id="B21"></a>21. Lund L, Edwards L, Kucheryavaya A, Dipchand A, Benden C, Christie J, et al. The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report&#x2013;2013; focus theme: age. <i>J Heart Lung Transplant.</i> (2013) 32:951&#x2013;64. doi: 10.1016/j.healun.2013.08.006</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24054804" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.healun.2013.08.006" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=The+registry+of+the+international+society+for+heart+and+lung+transplantation%3A+thirtieth+official+adult+heart+transplant+report&#x2013;2013;+focus+theme%3A+age%2E&#x0026;journal=J+Heart+Lung+Transplant%2E&#x0026;author=Lund+L&#x0026;author=Edwards+L&#x0026;author=Kucheryavaya+A&#x0026;author=Dipchand+A&#x0026;author=Benden+C&#x0026;author=Christie+J&#x0026;publication_year=2013&#x0026;volume=32&#x0026;pages=951&#x2013;64" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B22" id="B22"></a>22. Lane T, Fontana M, Martinez-Naharro A, Quarta C, Whelan C, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. <i>Circulation.</i> (2019) 140:16&#x2013;26.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Natural+history%2C+quality+of+life%2C+and+outcome+in+cardiac+transthyretin+amyloidosis%2E&#x0026;journal=Circulation%2E&#x0026;author=Lane+T&#x0026;author=Fontana+M&#x0026;author=Martinez-Naharro+A&#x0026;author=Quarta+C&#x0026;author=Whelan+C&#x0026;author=Petrie+A&#x0026;publication_year=2019&#x0026;volume=140&#x0026;pages=16&#x2013;26" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B23" id="B23"></a>23. Suhr O, Larsson M, Ericzon B, Wilczek H. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry. <i>Transplantation.</i> (2016) 100:373&#x2013;81. doi: 10.1097/TP.0000000000001021</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26656838" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/TP.0000000000001021" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Survival+after+transplantation+in+patients+with+mutations+other+than+Val30Met%3A+extracts+from+the+FAP+world+transplant+registry%2E&#x0026;journal=Transplantation%2E&#x0026;author=Suhr+O&#x0026;author=Larsson+M&#x0026;author=Ericzon+B&#x0026;author=Wilczek+H&#x0026;publication_year=2016&#x0026;volume=100&#x0026;pages=373&#x2013;81" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B24" id="B24"></a>24. Selvanayagam J, Hawkins P, Paul B, Myerson S, Neubauer S. Evaluation and management of the cardiac amyloidosis. <i>J Am Coll Cardiol.</i> (2007) 50:2101&#x2013;10.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Evaluation+and+management+of+the+cardiac+amyloidosis%2E&#x0026;journal=J+Am+Coll+Cardiol%2E&#x0026;author=Selvanayagam+J&#x0026;author=Hawkins+P&#x0026;author=Paul+B&#x0026;author=Myerson+S&#x0026;author=Neubauer+S&#x0026;publication_year=2007&#x0026;volume=50&#x0026;pages=2101&#x2013;10" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B25" id="B25"></a>25. Cardoso R, Graffunder F, Ternes C, Fernandes A, Rocha AV, Fernandes G, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. <i>EClinicalMedicine.</i> (2021) 36:100933. doi: 10.1016/j.eclinm.2021.100933</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34308311" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.eclinm.2021.100933" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=SGLT2+inhibitors+decrease+cardiovascular+death+and+heart+failure+hospitalizations+in+patients+with+heart+failure%3A+a+systematic+review+and+meta-analysis%2E&#x0026;journal=EClinicalMedicine%2E&#x0026;author=Cardoso+R&#x0026;author=Graffunder+F&#x0026;author=Ternes+C&#x0026;author=Fernandes+A&#x0026;author=Rocha+AV&#x0026;author=Fernandes+G&#x0026;publication_year=2021&#x0026;volume=36&#x0026;issue=100933" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B26" id="B26"></a>26. Hall R, Hawkins PN. Grand rounds-hammersmith hospital cardiac transplantation for AL amyloidosis. <i>BMJ.</i> (1994) 309:1135. doi: 10.1136/bmj.309.6962.1135</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/7987109" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/bmj.309.6962.1135" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Grand+rounds-hammersmith+hospital+cardiac+transplantation+for+AL+amyloidosis%2E&#x0026;journal=BMJ%2E&#x0026;author=Hall+R&#x0026;author=Hawkins+PN&#x0026;publication_year=1994&#x0026;volume=309&#x0026;issue=1135" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B27" id="B27"></a>27. Macdonald P, Peter Macdonald C. Heart transplantation: who should be considered and when? <i>Intern Med J.</i> (2008) 38:911&#x2013;7. doi: 10.1111/j.1445-5994.2008.01833.x</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19120548" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1445-5994.2008.01833.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Heart+transplantation%3A+who+should+be+considered+and+when%B4&#x0026;journal=Intern+Med+J%2E&#x0026;author=Macdonald+P&#x0026;author=Peter+Macdonald+C&#x0026;publication_year=2008&#x0026;volume=38&#x0026;pages=911&#x2013;7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B28" id="B28"></a>28. Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. <i>Heart Fail Rev.</i> (2015) 20:155&#x2013;62. doi: 10.1007/s10741-014-9464-5</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25447844" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10741-014-9464-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Natural+history+and+therapy+of+AL+cardiac+amyloidosis%2E&#x0026;journal=Heart+Fail+Rev%2E&#x0026;author=Grogan+M&#x0026;author=Dispenzieri+A&#x0026;publication_year=2015&#x0026;volume=20&#x0026;pages=155&#x2013;62" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B29" id="B29"></a>29. Pepys M. Amyloidosis. <i>Annu Rev Med.</i> (2006) 57:223&#x2013;41. doi: 10.1146/annurev.med.57.121304.131243</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16409147" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1146/annurev.med.57.121304.131243" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Amyloidosis%2E&#x0026;journal=Annu+Rev+Med%2E&#x0026;author=Pepys+M&#x0026;publication_year=2006&#x0026;volume=57&#x0026;pages=223&#x2013;41" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B30" id="B30"></a>30. Douglass C, Suvarna K, Reilly M, Hawkins P, Hadjivassiliou M. A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia. <i>J Neurol Neurosurg Psychiatry.</i> (2007) 78:193. doi: 10.1136/jnnp.2006.093500</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16971399" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jnnp.2006.093500" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+novel+amyloidogenic+transthyretin+variant%2C+Gly53Ala%2C+associated+with+intermittent+headaches+and+ataxia%2E&#x0026;journal=J+Neurol+Neurosurg+Psychiatry%2E&#x0026;author=Douglass+C&#x0026;author=Suvarna+K&#x0026;author=Reilly+M&#x0026;author=Hawkins+P&#x0026;author=Hadjivassiliou+M&#x0026;publication_year=2007&#x0026;volume=78&#x0026;issue=193" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B31" id="B31"></a>31. Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. <i>Curr Opin Neurol.</i> (2012) 25:564&#x2013;72. doi: 10.1097/WCO.0b013e328357bdf6</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22941262" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/WCO.0b013e328357bdf6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Amyloid+neuropathies%2E&#x0026;journal=Curr+Opin+Neurol%2E&#x0026;author=Adams+D&#x0026;author=Lozeron+P&#x0026;author=Lacroix+C&#x0026;publication_year=2012&#x0026;volume=25&#x0026;pages=564&#x2013;72" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B32" id="B32"></a>32. Sattianayagam P, Hahn A, Whelan C, Gibbs S, Pinney J, Stangou A, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. <i>Eur Heart J.</i> (2012) 33:1120&#x2013;7. doi: 10.1093/eurheartj/ehr383</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/21992998" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/eurheartj/ehr383" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+phenotype+and+clinical+outcome+of+familial+amyloid+polyneuropathy+associated+with+transthyretin+alanine+60+variant%2E&#x0026;journal=Eur+Heart+J%2E&#x0026;author=Sattianayagam+P&#x0026;author=Hahn+A&#x0026;author=Whelan+C&#x0026;author=Gibbs+S&#x0026;author=Pinney+J&#x0026;author=Stangou+A&#x0026;publication_year=2012&#x0026;volume=33&#x0026;pages=1120&#x2013;7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B33" id="B33"></a>33. Nelson L, Penninga L, Sander K, Hansen P, Villadsen G, Rasmussen A, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. <i>Clin Transplant.</i> (2013) 27:203&#x2013;9. doi: 10.1111/ctr.12053</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23278526" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/ctr.12053" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Long-term+outcome+in+patients+treated+with+combined+heart+and+liver+transplantation+for+familial+amyloidotic+cardiomyopathy%2E&#x0026;journal=Clin+Transplant%2E&#x0026;author=Nelson+L&#x0026;author=Penninga+L&#x0026;author=Sander+K&#x0026;author=Hansen+P&#x0026;author=Villadsen+G&#x0026;author=Rasmussen+A&#x0026;publication_year=2013&#x0026;volume=27&#x0026;pages=203&#x2013;9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B34" id="B34"></a>34. Ueno S, Uemichi T, Yorifuji S, Tarui S. A novel variant of transthyretin (Tyr114 to Cys) deduced from the nucleotide sequences of gene fragments from familial amyloidotic polyneuropathy in Japanese sibling cases. <i>Biochem Biophys Res Commun.</i> (1990) 169:143&#x2013;7. doi: 10.1016/0006-291x(90)91445-x</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/2161654" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/0006-291x(90)91445-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+novel+variant+of+transthyretin+%28Tyr114+to+Cys%29+deduced+from+the+nucleotide+sequences+of+gene+fragments+from+familial+amyloidotic+polyneuropathy+in+Japanese+sibling+cases%2E&#x0026;journal=Biochem+Biophys+Res+Commun%2E&#x0026;author=Ueno+S&#x0026;author=Uemichi+T&#x0026;author=Yorifuji+S&#x0026;author=Tarui+S&#x0026;publication_year=1990&#x0026;volume=169&#x0026;pages=143&#x2013;7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B35" id="B35"></a>35. Brett M, Persey M, Reilly M, Revesz T, Booth D, Booth S, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. <i>Brain.</i> (1999) 122(Pt. 2):183&#x2013;90. doi: 10.1093/brain/122.2.183</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/10071047" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/brain/122.2.183" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Transthyretin+Leu12Pro+is+associated+with+systemic%2C+neuropathic+and+leptomeningeal+amyloidosis%2E&#x0026;journal=Brain%2E&#x0026;author=Brett+M&#x0026;author=Persey+M&#x0026;author=Reilly+M&#x0026;author=Revesz+T&#x0026;author=Booth+D&#x0026;author=Booth+S&#x0026;publication_year=1999&#x0026;volume=122(Pt. 2)&#x0026;pages=183&#x2013;90" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B36" id="B36"></a>36. Nakagawa K, Sheikh S, Snuderl M, Frosch M, Greenberg SM. A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. <i>J Neurol Sci.</i> (2008) 272:186&#x2013;90. doi: 10.1016/j.jns.2008.05.014</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18579156" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jns.2008.05.014" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=A+new+Thr49Pro+transthyretin+gene+mutation+associated+with+leptomeningeal+amyloidosis%2E&#x0026;journal=J+Neurol+Sci%2E&#x0026;author=Nakagawa+K&#x0026;author=Sheikh+S&#x0026;author=Snuderl+M&#x0026;author=Frosch+M&#x0026;author=Greenberg+SM&#x0026;publication_year=2008&#x0026;volume=272&#x0026;pages=186&#x2013;90" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B37" id="B37"></a>37. Monteiro C, Martins da Silva A, Ferreira N, Mesgarzadeh J, Novais M, Coelho T, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. <i>Amyloid.</i> (2018) 25:120&#x2013;8. doi: 10.1080/13506129.2018.1479249</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29993288" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/13506129.2018.1479249" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Cerebrospinal+fluid+and+vitreous+body+exposure+to+orally+administered+tafamidis+in+hereditary+ATTRV30M+%28p%2ETTRV50M%29+amyloidosis+patients%2E&#x0026;journal=Amyloid%2E&#x0026;author=Monteiro+C&#x0026;author=Martins+da+Silva+A&#x0026;author=Ferreira+N&#x0026;author=Mesgarzadeh+J&#x0026;author=Novais+M&#x0026;author=Coelho+T&#x0026;publication_year=2018&#x0026;volume=25&#x0026;pages=120&#x2013;8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B38" id="B38"></a>38. Coelho T, Maia L, da Silva A, Cruz M, Plant&#x00E9;-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. <i>Neurology.</i> (2012) 79:785.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Tafamidis+for+transthyretin+familial+amyloid+polyneuropathy%3A+a+randomized%2C+controlled+trial%2E&#x0026;journal=Neurology%2E&#x0026;author=Coelho+T&#x0026;author=Maia+L&#x0026;author=da+Silva+A&#x0026;author=Cruz+M&#x0026;author=Plant&#x00E9;-Bordeneuve+V&#x0026;author=Lozeron+P&#x0026;publication_year=2012&#x0026;volume=79&#x0026;issue=785" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em;">
<p class="ReferencesCopy1"><a name="B39" id="B39"></a>39. Griffin J, Baughan E, Rosenblum H, Clerkin K, Fried J, Raikhelkar J, et al. Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. <i>J Heart Lung Transpl.</i> (2022) 41:199&#x2013;207. doi: 10.1016/j.healun.2021.10.007</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/34922822" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.healun.2021.10.007" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?&#x0026;title=Surveillance+for+disease+progression+of+transthyretin+amyloidosis+after+heart+transplantation+in+the+era+of+novel+disease+modifying+therapies%2E&#x0026;journal=J+Heart+Lung+Transpl%2E&#x0026;author=Griffin+J&#x0026;author=Baughan+E&#x0026;author=Rosenblum+H&#x0026;author=Clerkin+K&#x0026;author=Fried+J&#x0026;author=Raikhelkar+J&#x0026;publication_year=2022&#x0026;volume=41&#x0026;pages=199&#x2013;207" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords</span>: amyloid, transplant, heart failure, TTR&#x2013;transthyretin, outcome</p>
<p><span>Citation:</span> Razvi Y, Porcari A, Di Nora C, Patel RK, Ioannou A, Rauf MU, Masi A, Law S, Chacko L, Rezk T, Ravichandran S, Gilbertson J, Rowczenio D, Blakeney IJ, Kaza N, Hutt DF, Lachmann H, Wechalekar A, Moody W, Lim S, Chue C, Whelan C, Venneri L, Martinez-Naharro A, Merlo M, Sinagra G, Livi U, Hawkins P, Fontana M and Gillmore JD (2023) Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience. <i>Front. Cardiovasc. Med.</i> 9:1075806. doi: 10.3389/fcvm.2022.1075806</p>
<p id="timestamps">
<span>Received:</span> 20 October 2022; <span>Accepted:</span> 23 December 2022;<br><span>Published:</span> 19 January 2023.</p>
<div>
<p>Edited by:</p>
<a href="https://loop.frontiersin.org/people/1111136/overview">Giovanni Quarta</a>, Papa Giovanni XXIII Hospital, Italy</div>
<div>
<p>Reviewed by:</p>
<a href="https://loop.frontiersin.org/people/1282987/overview">Beatrice Musumeci</a>, Sapienza University of Rome, Italy<br>
<a href="https://loop.frontiersin.org/people/1655841/overview">Yasuhiro Izumiya</a>, Osaka City University, Japan</div>
<p><span>Copyright</span> &#x00A9; 2023 Razvi, Porcari, Di Nora, Patel, Ioannou, Rauf, Masi, Law, Chacko, Rezk, Ravichandran, Gilbertson, Rowczenio, Blakeney, Kaza, Hutt, Lachmann, Wechalekar, Moody, Lim, Chue, Whelan, Venneri, Martinez-Naharro, Merlo, Sinagra, Livi, Hawkins, Fontana and Gillmore. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>*Correspondence:</span> Julian D. Gillmore, <img src="https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/email.jpg" alt="www.frontiersin.org" > <a id="encmail">ai5naWxsbW9yZUB1Y2wuYWMudWs=</a></p>
<p><sup>&#x2020;</sup>These authors have contributed equally to this work and share first authorship</p>
<p><sup>&#x2021;</sup>These authors have contributed equally to this work and share last authorship</p>
<div class="clear"></div>
</div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fcvm.2022.1075806" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">3,6K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,3K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">19</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1075806#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fcvm.2022.1075806" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fcvm.2022.1075806" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/1111136/overview" data-event="editorInfo-a-giovanniQuarta" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">G</span><span class="notranslate">Q</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Giovanni  Quarta</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Papa Giovanni XXIII Hospital, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/1655841/overview" data-event="editorInfo-a-yasuhiroIzumiya" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">Y</span><span class="notranslate">I</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Yasuhiro  Izumiya</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Kumamoto University, Japan</div></div></a><a href="https://loop.frontiersin.org/people/1282987/overview" data-event="editorInfo-a-beatriceMusumeci" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">B</span><span class="notranslate">M</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Beatrice  Musumeci</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Sapienza University of Rome, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Materials and methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Data availability statement</a></li>
<li><a href="#h7">Author contributions</a></li>
<li><a href="#h17">Funding</a></li>
<li><a href="#h8">Conflict of interest</a></li>
<li><a href="#h9">Publisher&#x2019;s note</a></li>
<li><a href="#h10">Supplementary material</a></li>
<li><a href="#h11">Abbreviations</a></li>
<li><a href="#h12">References</a></li>
</ul>
</div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fcvm.2022.1075806" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full",["Reactive",16],{"main":17,"user":529,"article":530,"articleHub":1077,"mainHeader":1081},{"ibar":18,"footer":292,"newsletterComponent":-1,"snackbarItem":374,"toggleShowSnackbar":375,"contentfulJournal":376,"graphJournal":430,"settingsFeaturesSwitchers":434,"templateToggleBanner":435,"tenantConfig":494},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":223,"aboutJournal":224,"mainLinks":273,"journalLinks":280,"helpCenterLink":289},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=103&specialtyid=0&entitytype=2&entityid=755",{"id":115,"name":116,"slug":117,"sections":118},755,"Frontiers in Cardiovascular Medicine","cardiovascular-medicine",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211,215,219],{"id":120,"name":121,"slug":122},3114,"Aortic Surgery and Endovascular Repair Archive","aortic-surgery-and-endovascular-repair-archive",{"id":124,"name":125,"slug":126},857,"Atherosclerosis and Vascular Medicine","atherosclerosis-and-vascular-medicine",{"id":128,"name":129,"slug":130},849,"Cardiac Rhythmology","cardiac-rhythmology",{"id":132,"name":133,"slug":134},1513,"Cardio-Oncology","cardio-oncology",{"id":136,"name":137,"slug":138},3205,"Cardioneurology","cardioneurology",{"id":140,"name":141,"slug":142},855,"Cardiovascular Biologics and Regenerative Medicine","cardiovascular-biologics-and-regenerative-medicine",{"id":144,"name":145,"slug":146},802,"Cardiovascular Epidemiology and Prevention","cardiovascular-epidemiology-and-prevention",{"id":148,"name":149,"slug":150},847,"Cardiovascular Genetics and Systems Medicine","cardiovascular-genetics-and-systems-medicine",{"id":152,"name":153,"slug":154},813,"Cardiovascular Imaging","cardiovascular-imaging",{"id":156,"name":157,"slug":158},959,"Cardiovascular Metabolism","cardiovascular-metabolism",{"id":160,"name":161,"slug":162},3689,"Cardiovascular Nursing","cardiovascular-nursing",{"id":164,"name":165,"slug":166},3150,"Cardiovascular Pharmacology and Drug Discovery","cardiovascular-pharmacology-and-drug-discovery",{"id":168,"name":169,"slug":170},816,"Cardiovascular Surgery","cardiovascular-surgery",{"id":172,"name":173,"slug":174},3149,"Clinical and Translational Cardiovascular Medicine","clinical-and-translational-cardiovascular-medicine",{"id":176,"name":177,"slug":178},2001,"Coronary Artery Disease","coronary-artery-disease",{"id":180,"name":181,"slug":182},850,"General Cardiovascular Medicine","general-cardiovascular-medicine",{"id":184,"name":185,"slug":186},851,"Heart Failure and Transplantation","heart-failure-and-transplantation",{"id":188,"name":189,"slug":190},1829,"Heart Valve Disease","heart-valve-disease",{"id":192,"name":193,"slug":194},820,"Hypertension","hypertension",{"id":196,"name":197,"slug":198},3206,"Intensive Care Cardiovascular Medicine","intensive-care-cardiovascular-medicine",{"id":200,"name":201,"slug":202},2112,"Lipids in Cardiovascular Disease","lipids-in-cardiovascular-disease",{"id":204,"name":205,"slug":206},613,"Pediatric Cardiology","pediatric-cardiology",{"id":208,"name":209,"slug":210},3415,"Precision Cardiology","precision-cardiology",{"id":212,"name":213,"slug":214},1832,"Sex and Gender in Cardiovascular Medicine","sex-and-gender-in-cardiovascular-medicine",{"id":216,"name":217,"slug":218},1325,"Structural Interventional Cardiology","structural-interventional-cardiology",{"id":220,"name":221,"slug":222},2018,"Thrombosis and Haemostasis","thrombosis-and-haemostasis","Sections",[225,249],{"title":226,"links":227},"Scope",[228,231,234,237,240,243,246],{"text":229,"url":230,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-editors",{"text":232,"url":233,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-scope",{"text":235,"url":236,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-facts",{"text":238,"url":239,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-submission",{"text":241,"url":242,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-open",{"text":244,"url":245,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/cardiovascular-medicine/about#copyright-statement",{"text":247,"url":248,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/cardiovascular-medicine/about#about-quality",{"title":250,"links":251},"For authors",[252,255,258,261,264,267,270],{"text":253,"url":254,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/why-submit",{"text":256,"url":257,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/article-types",{"text":259,"url":260,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/author-guidelines",{"text":262,"url":263,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/editor-guidelines",{"text":265,"url":266,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/publishing-fees",{"text":268,"url":269,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/submission-checklist",{"text":271,"url":272,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/cardiovascular-medicine/for-authors/contact-editorial-office",[274,277],{"text":275,"url":276,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":278,"url":279,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[281,284,286],{"text":282,"url":283,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":285,"target":27,"ariaLabel":28},"research-topics",{"text":287,"url":288,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":290,"url":291,"target":77,"ariaLabel":290},"Help center","https://helpcenter.frontiersin.org",{"blocks":293,"socialLinks":347,"copyright":371,"termsAndConditionsUrl":372,"privacyPolicyUrl":373},[294,308,318,332],{"title":295,"links":296},"Guidelines",[297,299,302,305,307],{"text":259,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":300,"url":301,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":303,"url":304,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":262,"url":306,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":309,"links":310},"Explore",[311,312,315,317],{"text":282,"url":279,"target":27,"ariaLabel":28},{"text":313,"url":314,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":316,"url":276,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":319,"links":320},"Outreach",[321,324,327,331],{"text":322,"url":92,"target":77,"ariaLabel":323},"Frontiers Forum ","Frontiers Forum website",{"text":325,"url":326,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":328,"url":329,"target":77,"ariaLabel":330},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":333,"links":334},"Connect",[335,336,340,343,346],{"text":290,"url":291,"target":77,"ariaLabel":290},{"text":337,"url":338,"target":77,"ariaLabel":339},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":341,"url":111,"target":27,"ariaLabel":342},"Contact us ","Subscribe to newsletter",{"text":344,"url":345,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[348,356,361,366],{"link":349,"type":352,"color":353,"icon":354,"size":355,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":350},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":357,"type":352,"color":353,"icon":360,"size":355,"hiddenText":13},{"text":358,"url":359,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":362,"type":352,"color":353,"icon":365,"size":355,"hiddenText":13},{"text":363,"url":364,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":367,"type":352,"color":353,"icon":370,"size":355,"hiddenText":13},{"text":368,"url":369,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":377,"identifier":115,"name":116,"slug":117,"banner":378,"description":423,"mission":424,"palette":425,"impactFactor":426,"citeScore":427,"citations":428,"showTagline":28,"twitter":429},"Journal",[379],{"id":380,"src":381,"name":382,"type":383,"width":384,"height":385,"idHash":386,"archive":387,"brandId":388,"limited":387,"fileSize":389,"isPublic":390,"original":391,"copyright":19,"extension":392,"thumbnails":394,"dateCreated":402,"description":19,"orientation":403,"userCreated":404,"watermarked":387,"dateModified":402,"datePublished":405,"ecsArchiveFiles":406,"propertyOptions":407,"property_Channel":412,"property_Sub-Type":414,"property_Asset_Type":416,"activeOriginalFocusPoint":418,"property_Office_Department":421},"0E097865-0E34-4E8F-84C1727DD698619A","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/webimage-26D7D41D-2261-478D-A085B8C607B76316.png","FCVM_Main Visual_Red_Website","image",4928,3264,"3d4ead6d0ff9ddd0",0,"22C10171-81B3-4DA6-99342F272A32E8BB",996380,1,"https://brand.frontiersin.org/m/3d4ead6d0ff9ddd0/original/FCVM_Main-Visual_Red_Website.jpg",[393],"jpg",{"mini":395,"thul":396,"webimage":381,"Guidelines":397,"WebsiteJpg_XL":398,"WebsiteWebP_L":399,"WebsiteWebP_M":400,"WebsiteWebP_XL":401},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/mini-D3B4A072-4891-48D0-A1517AD0B515C67C.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/thul-862A7E98-77F8-406C-935A26D93CF11874.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/Guidelines-FCVM_Main Visual_Red_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteJpg_XL-FCVM_Main Visual_Red_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteWebP_L-FCVM_Main Visual_Red_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteWebP_M-FCVM_Main Visual_Red_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0E097865-0E34-4E8F-84C1727DD698619A/41A3C274-4936-4899-BCC78909330BD4F9/WebsiteWebP_XL-FCVM_Main Visual_Red_Website.webp","2022-06-27T09:59:15Z","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[408,409,410,411],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[413],"frontiersin_org",[415],"Main_Visual",[417],"Photography",{"x":419,"y":420},2464,1632,[422],"Publishing","Multidisciplinary journal publishing peer-reviewed research across basic, translational, and clinical cardiovascular medicine.","\u003Cp>Frontiers in Cardiovascular Medicine is a multidisciplinary journal that publishes research articles across basic, translational, and clinical cardiovascular medicine.\u003C/p>\n\n\u003Cp>Led by Field Chief Editors Dr Masanori Aikawa (Brigham Womens Hospital, USA) and Dr Hendrik Tevaearai Stahel (University Hospital of Bern, Switzerland) Frontiers in Cardiovascular Medicine covers all aspects of cardiovascular medicine, with an emphasis on studies that challenge the status quo of treatments and practices or facilitate the translation of scientific advances into the clinic.\u003C/p>\n\n\u003Cp>Topics include, but are not limited to:\u003C/p>\n\n\u003Cdiv>&bull; atherosclerosis and vascular medicine\u003C/div>\n\u003Cdiv>&bull; cardiac rhythmology\u003C/div>\n\u003Cdiv>&bull; cardio-oncology\u003C/div>\n\u003Cdiv>&bull; cardioneurology\u003C/div>\n\u003Cdiv>&bull; cardiovascular epidemiology and prevention\u003C/div>\n\u003Cdiv>&bull; cardiovascular genetics and systems medicine\u003C/div>\n\u003Cdiv>&bull; cardiovascular imaging\u003C/div>\n\u003Cdiv>&bull; cardiovascular metabolism\u003C/div>\n\u003Cdiv>&bull; cardiovascular nursing\u003C/div>\n\u003Cdiv>&bull; cardiovascular pharmacology and drug discovery\u003C/div>\n\u003Cdiv>&bull; cardiovascular surgery\u003C/div>\n\u003Cdiv>&bull; clinical and translational cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; coronary artery disease\u003C/div>\n\u003Cdiv>&bull; general cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; heart failure and transplantation\u003C/div>\n\u003Cdiv>&bull; heart valve disease\u003C/div>\n\u003Cdiv>&bull; hypertension\u003C/div>\n\u003Cdiv>&bull; intensive care cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; lipids in cardiovascular disease\u003C/div>\n\u003Cdiv>&bull; pediatric cardiology\u003C/div>\n\u003Cdiv>&bull; precision cardiology\u003C/div>\n\u003Cdiv>&bull; sex and gender in cardiovascular medicine\u003C/div>\n\u003Cdiv>&bull; structural interventional cardiology\u003C/div>\n\u003Cdiv>&bull; thrombosis and haemostasis.\u003C/div>\n\u003Cbr>\n\u003Cp>Both fundamental mechanistic studies of cardiovascular disease and translational research that can bring new discoveries to patients quickly are welcome. The editors are especially interested in submissions that employ a systems approach driven by data science. \n\u003Cp>Frontiers journals require that manuscripts primarily comprising computational studies of public data, such as NHANES or Mendelian Randomization studies, must include appropriate validation. The journal is not considering bibliometric studies. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information. Manuscripts not adhering to these standards will not be considered. \n\n\u003Cp>In particular, the journal welcomes submissions that support and advance the UNs Sustainable Development Goal (SDG), notably SDG#3: Ensure healthy lives and promote well-being for all at all ages.\u003C/p> \n\n\u003Cp>Frontiers in Cardiovascular Medicine is committed to advancing developments in the field of cardiovascular medicine by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","red","3.6","2.6","110175","@FrontCVMedicine",{"id":115,"name":116,"slug":117,"abbreviation":431,"isOnline":13,"isOpenForSubmissions":13,"citeScore":432,"impactFactor":433},"fcvm",5.5,2.9,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":375},{"isPublic":13,"allowCompanyUsers":375,"whiteListEmails":436,"enableAllJournals":13,"whiteListJournals":458},[437,438,439,440,441,442,443,444,445,442,446,447,448,449,450,451,452,453,454,455,456,457],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[459,460,461,462,463,464,390,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,115,491,492,493],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,2136,609,1534,{"spaceId":390,"name":390,"availableJournalPages":495,"announcement":499},[283,288,285,496,497,498],"volumes","about","community-reviewers",{"__typename":500,"sys":501,"preHeader":42,"title":503,"description":504,"image":505,"link":527},"Announcement",{"id":502},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[506],{"archive":387,"brandId":388,"copyright":28,"dateCreated":507,"dateModified":508,"datePublished":509,"description":28,"extension":510,"fileSize":512,"height":513,"id":514,"isPublic":387,"limited":387,"name":515,"orientation":403,"original":28,"thumbnails":516,"type":383,"watermarked":387,"width":523,"videoPreviewURLs":524,"tags":525,"textMetaproperties":526,"src":517},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[511],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":517,"thul":518,"mini":519,"WebsiteWebP_L":520,"WebsiteWebP_M":521,"Guidelines":522},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":528,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":531,"isPreviewPage":375,"hasSupplementalData":375,"showCrossmarkWidget":13,"articleTemplate":825,"currentArticlePageMetaInfo":826,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":532,"doi":533,"title":534,"acceptanceDate":535,"receptionDate":536,"publicationDate":537,"lastModifiedDate":538,"isPublished":13,"abstract":539,"researchTopic":540,"articleType":546,"stage":549,"keywords":551,"authors":557,"editors":754,"reviewers":763,"journal":781,"section":789,"impactMetrics":791,"volume":794,"articleVolume":795,"relatedArticles":796,"isPublishedV2":375,"contents":797,"files":800},1075806,"10.3389/fcvm.2022.1075806","Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience",["Date","2022-12-23T16:34:16.000Z"],["Date","2022-10-20T22:42:21.000Z"],["Date","2023-01-19T00:00:00.000Z"],["Date","2025-11-25T03:32:21.512Z"],"Abstract\nAims\nTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy.  Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT).  Despite case series demonstrating comparable outcomes with CT between patients with ATTR-CM and non-amyloid cardiomyopathies, ATTR-CM is considered to be a contraindication to CT in some centres, partly due to a perceived risk of amyloid recurrence in the allograft.  We report long-term outcomes of CT in ATTR-CM at two tertiary centres.\n\nMethods and Results\nWe retrospectively evaluated ATTR-CM patients across two tertiary centres who underwent transplantation between 1990 and 2020.  Pre-transplantation characteristics were determined and outcomes were compared with a cohort of non-transplanted ATTR-CM patients.  \n\nFourteen (12 male, 2 female) patients with ATTR-CM underwent CT including 11 with wild-type ATTR-CM and 3 with variant ATTR-CM (ATTRv).  Median age at CT was 62 years and median follow up post-CT was 66 months.  One, three, and five-year survival was 100%, 92% and 90%, respectively and the longest surviving patient was censored >19 years post CT.  No patients had recurrence of amyloid in the cardiac allograft.  Four patients died, including one with ATTRv-CM from complications of leptomeningeal amyloidosis.  Survival among the cohort of patients who underwent CT was significantly prolonged compared to UK patients with ATTR-CM generally (p\u003C0.001) including those diagnosed under age 65 years (p=0.008) or with early stage cardiomyopathy (p\u003C0.001). \n\nConclusion\nCT is well-tolerated, restores functional capacity and improves prognosis in ATTR-CM.  The risk of amyloid recurrence in the cardiac allograft appears to be low.",{"id":541,"title":542,"articlesCount":543,"isMagazinePage":13,"slug":544,"isOpenForSubmission":375,"views":545},40041,"Proceedings and Predictions in Cardiac Amyloidosis: Unsolved mysteries and challenges for the future",11,"proceedings-and-predictions-in-cardiac-amyloidosis-unsolved-mysteries-and-challenges-for-the-future",63962,{"id":547,"name":548},24,"Original Research",{"id":550,"name":19},18,[552,553,554,555,556],"Amyloid","transplant","Heart Failure","TTR = transthyretin","Outcome",[558,567,576,583,590,596,603,610,616,623,629,635,641,647,653,660,666,672,678,686,692,698,704,711,717,723,729,735,741,747],{"id":559,"firstName":560,"middleName":19,"lastName":561,"givenNames":562,"isCorresponding":375,"isProfilePublic":13,"userId":559,"email":-1,"affiliations":563},1426416,"Yousuf","Razvi","Yousuf ",[564],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},"Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London","United Kingdom",{"id":387,"firstName":568,"middleName":19,"lastName":569,"givenNames":570,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":571},"Aldostefano","Porcari","Aldostefano ",[572,573],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":574,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},"Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste","Italy",{"id":387,"firstName":577,"middleName":19,"lastName":578,"givenNames":579,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":580},"Concetta","Di Nora","Concetta ",[581],{"organizationName":582,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},"Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine",{"id":584,"firstName":585,"middleName":19,"lastName":586,"givenNames":587,"isCorresponding":375,"isProfilePublic":13,"userId":584,"email":-1,"affiliations":588},1551116,"Rishi K.","Patel","Rishi K. ",[589],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":591,"middleName":19,"lastName":592,"givenNames":593,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":594},"Adam","Ioannou","Adam ",[595],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":597,"firstName":598,"middleName":19,"lastName":599,"givenNames":600,"isCorresponding":375,"isProfilePublic":13,"userId":597,"email":-1,"affiliations":601},2143756,"Muhammad U.","Rauf","Muhammad U. ",[602],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":604,"firstName":605,"middleName":19,"lastName":606,"givenNames":607,"isCorresponding":375,"isProfilePublic":13,"userId":604,"email":-1,"affiliations":608},2077411,"Ambra","Masi","Ambra ",[609],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":611,"middleName":19,"lastName":612,"givenNames":613,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":614},"Steven","Law","Steven ",[615],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":617,"firstName":618,"middleName":19,"lastName":619,"givenNames":620,"isCorresponding":375,"isProfilePublic":13,"userId":617,"email":-1,"affiliations":621},1436772,"Liza","Chacko","Liza ",[622],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":624,"middleName":19,"lastName":625,"givenNames":626,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":627},"Tamer","Rezk","Tamer ",[628],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":630,"middleName":19,"lastName":631,"givenNames":632,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":633},"Sriram","Ravichandran","Sriram ",[634],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":636,"middleName":19,"lastName":637,"givenNames":638,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":639},"Janet","Gilbertson","Janet ",[640],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":642,"middleName":19,"lastName":643,"givenNames":644,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":645},"Dorota","Rowczenio","Dorota ",[646],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":648,"middleName":19,"lastName":649,"givenNames":650,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":651},"Iona J.","Blakeney","Iona J. ",[652],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":654,"middleName":19,"lastName":655,"givenNames":656,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":657},"Nandita","Kaza","Nandita ",[658],{"organizationName":659,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},"Imperial College London",{"id":387,"firstName":661,"middleName":19,"lastName":662,"givenNames":663,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":664},"David F.","Hutt","David F. ",[665],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":667,"middleName":19,"lastName":668,"givenNames":669,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":670},"Helen","Lachmann","Helen ",[671],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":673,"middleName":19,"lastName":674,"givenNames":675,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":676},"Ashutosh","Wechalekar","Ashutosh ",[677],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":679,"firstName":680,"middleName":19,"lastName":681,"givenNames":682,"isCorresponding":375,"isProfilePublic":13,"userId":679,"email":-1,"affiliations":683},1222376,"William","Moody","William ",[684],{"organizationName":685,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},"Department of Cardiology, Queen Elizabeth Hospital Birmingham",{"id":387,"firstName":687,"middleName":19,"lastName":688,"givenNames":689,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":690},"Sern","Lim","Sern ",[691],{"organizationName":685,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":693,"middleName":19,"lastName":694,"givenNames":695,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":696},"Colin","Chue","Colin ",[697],{"organizationName":685,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":699,"middleName":19,"lastName":700,"givenNames":701,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":702},"Carol","Whelan","Carol ",[703],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":705,"firstName":706,"middleName":19,"lastName":707,"givenNames":708,"isCorresponding":375,"isProfilePublic":13,"userId":705,"email":-1,"affiliations":709},1878223,"Lucia","Venneri","Lucia ",[710],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":712,"middleName":19,"lastName":713,"givenNames":714,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":715},"Ana","Martinez-Naharro","Ana ",[716],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":718,"middleName":19,"lastName":719,"givenNames":720,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":721},"Marco","Merlo","Marco ",[722],{"organizationName":574,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":724,"middleName":19,"lastName":725,"givenNames":726,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":727},"Gianfranco","Sinagra","Gianfranco ",[728],{"organizationName":574,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":730,"middleName":19,"lastName":731,"givenNames":732,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":733},"Ugolino","Livi","Ugolino ",[734],{"organizationName":582,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":736,"middleName":19,"lastName":737,"givenNames":738,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":739},"Philip","Hawkins","Philip ",[740],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":387,"firstName":742,"middleName":19,"lastName":743,"givenNames":744,"isCorresponding":375,"isProfilePublic":375,"userId":387,"email":-1,"affiliations":745},"Marianna","Fontana","Marianna ",[746],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},{"id":748,"firstName":749,"middleName":19,"lastName":750,"givenNames":751,"isCorresponding":375,"isProfilePublic":13,"userId":748,"email":-1,"affiliations":752},2066247,"Julian D.","Gillmore","Julian D. ",[753],{"organizationName":565,"countryName":566,"cityName":19,"stateName":19,"zipCode":19},[755],{"id":756,"firstName":757,"middleName":19,"lastName":758,"givenNames":759,"isCorresponding":375,"isProfilePublic":13,"userId":756,"email":-1,"affiliations":760},1111136,"Giovanni","Quarta","Giovanni ",[761],{"organizationName":762,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},"Papa Giovanni XXIII Hospital",[764,773],{"id":765,"firstName":766,"middleName":19,"lastName":767,"givenNames":768,"isCorresponding":375,"isProfilePublic":13,"userId":765,"email":-1,"affiliations":769},1655841,"Yasuhiro","Izumiya","Yasuhiro ",[770],{"organizationName":771,"countryName":772,"cityName":19,"stateName":19,"zipCode":19},"Kumamoto University","Japan",{"id":774,"firstName":775,"middleName":19,"lastName":776,"givenNames":777,"isCorresponding":375,"isProfilePublic":13,"userId":774,"email":-1,"affiliations":778},1282987,"Beatrice","Musumeci","Beatrice ",[779],{"organizationName":780,"countryName":575,"cityName":19,"stateName":19,"zipCode":19},"Sapienza University of Rome",{"id":115,"slug":117,"name":116,"shortName":782,"electronicISSN":783,"field":784,"specialtyId":28,"journalSectionPaths":787},"Front. Cardiovasc. Med.","2297-055X",{"id":785,"domainId":786},103,2,[788],{"section":789},{"id":180,"name":181,"slug":182,"specialtyId":790},1574,{"views":792,"downloads":216,"citations":793},3591,19,9,"Volume 9 - 2022",[],{"titleHtml":534,"fullTextHtml":798,"menuHtml":799},"\u003Cdiv class=\"JournalAbstract\">\r\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\r\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\r\n\u003Ca href=\"https://loop.frontiersin.org/people/1426416\" class=\"user-id-1426416\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1426416/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\r\nYousuf Razvi&#x;\">Yousuf Razvi\u003C/a>\u003Csup>1&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Aldostefano Porcari,&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Aldostefano Porcari\u003Csup>1,2&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Concetta Di Nora\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Concetta Di Nora\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1551116\" class=\"user-id-1551116\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1551116/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Rishi K. Patel\">Rishi K. Patel\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Adam Ioannou\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Adam Ioannou\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2143756\" class=\"user-id-2143756\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2143756/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Muhammad U. Rauf\">Muhammad U. Rauf\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2077411\" class=\"user-id-2077411\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2077411/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ambra Masi\">Ambra Masi\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Steven Law\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Steven Law\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1436772\" class=\"user-id-1436772\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1436772/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Liza Chacko\">Liza Chacko\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Tamer Rezk\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Tamer Rezk\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sriram Ravichandran\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sriram Ravichandran\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Janet Gilbertson\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Janet Gilbertson\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Dorota Rowczenio\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Dorota Rowczenio\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Iona J. Blakeney\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Iona J. Blakeney\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Nandita Kaza\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Nandita Kaza\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"David F. Hutt\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">David F. Hutt\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Helen Lachmann\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Helen Lachmann\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Ashutosh Wechalekar\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Ashutosh Wechalekar\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1222376\" class=\"user-id-1222376\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1222376/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"William Moody\">William Moody\u003C/a>\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sern Lim\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sern Lim\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Colin Chue\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Colin Chue\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Carol Whelan\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Carol Whelan\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1878223\" class=\"user-id-1878223\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1878223/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Lucia Venneri\">Lucia Venneri\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Ana Martinez-Naharro\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Ana Martinez-Naharro\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Marco Merlo\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Marco Merlo\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Gianfranco Sinagra\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Gianfranco Sinagra\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Ugolino Livi\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Ugolino Livi\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Philip Hawkins\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Philip Hawkins\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Marianna Fontana&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Marianna Fontana\u003Csup>1&#x2021;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/2066247\" class=\"user-id-2066247\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/2066247/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Julian D. Gillmore*&#x;\">Julian D. Gillmore\u003C/a>\u003Csup>1*&#x2021;\u003C/sup>\u003C/span>\u003C/div>\r\n\u003Cul class=\"notes\">\r\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, London, United Kingdom\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Imperial College London, London, United Kingdom\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom\u003C/li>\r\n\u003C/ul>\r\n\u003Cp class=\"mb15\">\u003Cb>Aims:\u003C/b> Transthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy. Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT). Despite case series demonstrating comparable outcomes with CT between patients with ATTR-CM and non-amyloid cardiomyopathies, ATTR-CM is considered to be a contraindication to CT in some centers, partly due to a perceived risk of amyloid recurrence in the allograft. We report long-term outcomes of CT in ATTR-CM at two tertiary centers.\u003C/p>\r\n\u003Cp class=\"mb15\">\u003Cb>Materials and methods and Results:\u003C/b> We retrospectively evaluated ATTR-CM patients across two tertiary centers who underwent transplantation between 1990 and 2020. Pre-transplantation characteristics were determined and outcomes were compared with a cohort of non-transplanted ATTR-CM patients. Fourteen (12 male, 2 female) patients with ATTR-CM underwent CT including 11 with wild-type ATTR-CM and 3 with variant ATTR-CM (ATTRv). Median age at CT was 62 years and median follow up post-CT was 66 months. One, three, and five-year survival was 100, 92, and 90%, respectively and the longest surviving patient was Censored &#x003E; 19 years post CT. No patients had recurrence of amyloid in the cardiac allograft. Four patients died, including one with ATTRv-CM from complications of leptomeningeal amyloidosis. Survival among the cohort of patients who underwent CT was significantly prolonged compared to UK patients with ATTR-CM generally (\u003Ci>p\u003C/i> &#x003C; 0.001) including those diagnosed under age 65 years (\u003Ci>p\u003C/i> = 0.008) or with early stage cardiomyopathy (\u003Ci>p\u003C/i> &#x003C; 0.001).\u003C/p>\r\n\u003Cp class=\"mb0\">\u003Cb>Conclusion:\u003C/b> CT is well-tolerated, restores functional capacity and improves prognosis in ATTR-CM. The risk of amyloid recurrence in the cardiac allograft appears to be low.\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"JournalFullText\">\r\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\r\n\u003Cp class=\"mb15\">Systemic amyloidosis is characterized by extracellular tissue deposition of misfolded fibrillary protein. Amyloid is identified \u003Ci>ex vivo\u003C/i> by apple green birefringence when a tissue biopsy is stained with Congo red dye and viewed under cross-polarized light (\u003Ca href=\"#B1\">1\u003C/a>). A variety of normally soluble proteins, known as &#x201C;fibril precursor proteins,&#x201D; have been identified which can misfold and self-assemble with an abnormal cross beta-sheet conformation resulting in fibrils that are proteolysis resistant (\u003Ca href=\"#B2\">2\u003C/a>). These different &#x201C;amyloidogenic&#x201D; proteins form the basis for the classification of amyloidosis. Clinical disease occurs when amyloid deposits disrupt tissue structure and function. Whilst amyloid deposition can occur in almost any organ of the body, cardiac amyloidosis is the established leading cause of mortality in systemic amyloidosis (\u003Ca href=\"#B3\">3\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Transthyretin amyloid cardiomyopathy (ATTR-CM) is the most commonly diagnosed type of cardiac amyloidosis and may be either acquired (ATTRwt-CM) or associated with inheritance of a TTR variant (ATTRv-CM) (\u003Ca href=\"#B2\">2\u003C/a>). Historically, treatment for this inexorably progressive and ultimately fatal cardiomyopathy was supportive with meticulous fluid balance and diuretic therapy. However there have been landmark developments in disease-modifying therapy for patients with ATTR amyloidosis. Examples include TTR specific RNA interference or antisense oligonucleotide therapies such as patisiran and inotersen, TTR stabilizers such as tafamidis and acoramidis (\u003Ca href=\"#B4\">4\u003C/a>&#x2013;\u003Ca href=\"#B6\">6\u003C/a>), and the CRISPR/Cas9 based gene-editing therapy NTLA-2001 (\u003Ca href=\"#B7\">7\u003C/a>). Whilst these agents show promise, to date they appear to slow or potentially halt disease progression rather than being curative. Treatments that bring about an overt clinical improvement and genuinely improve quality of life in patients with advanced ATTR-CM remain elusive.\u003C/p>\r\n\u003Cp class=\"mb0\">Cardiac transplantation (CT) for patients with ATTRv-CM was first reported in 2003 (\u003Ca href=\"#B8\">8\u003C/a>). However, this was in the context of combined hepatic and CT, the dual objectives being to replace failing cardiac function and remove hepatic production of circulating variant, amyloidogenic TTR which is entirely liver-derived. Hepatic transplantation was mostly undertaken in young patients with hereditary ATTR amyloid polyneuropathy (ATTRv-PN) who typically carried the p.(Val50Met) TTR variant (\u003Ca href=\"#B9\">9\u003C/a>). In patients with ATTRv-PN deemed suitable for liver transplantation who had concurrent amyloid cardiomyopathy, a combined hepatic and cardiac transplant would sometimes be offered (\u003Ca href=\"#B10\">10\u003C/a>). However, the need for hepatic transplantation in patients with a predominant neuropathic ATTR amyloidosis has largely been superseded by the availability of aforementioned patisiran and inotersen, both of which have been shown to slow or halt disease progression. Consequently, younger patients with advanced ATTR-CM including ATTRwt-CM are increasingly considered for isolated CT (\u003Ca href=\"#B11\">11\u003C/a>). There is a paucity of published data on long term outcomes in patients who receive CT for ATTR-CM (\u003Ca href=\"#B11\">11\u003C/a>, \u003Ca href=\"#B12\">12\u003C/a>). Allograft amyloid recurrence and accumulation in extra-cardiac organs have remained key concerns in patients with AL amyloidosis receiving CT (either isolated, or combined) (\u003Ca href=\"#B13\">13\u003C/a>), and similar concerns regarding potential amyloid recurrence exist in ATTR-CM. Whilst patisiran and inotersen are effective at slowing ATTR amyloid production, they remain licensed only for patients with ATTRv-PN. The risk of cardiac allograft amyloid recurrence is therefore potentially greater in patients, such as those with ATTRwt-CM, who do not routinely receive TTR suppressing agents. We present multicentre outcomes with CT in 14 patients with ATTR-CM evaluated at the UK National Amyloidosis Center and the Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.\u003C/p>\r\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and methods\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Patients\u003C/h3>\r\n\u003Cp class=\"mb15\">All patients with ATTR-CM who attended the aforementioned tertiary centers and underwent CT between November 1991 and March 2020 were retrospectively identified from the institutions&#x2019; respective databases. Patients who underwent combined liver and heart transplant were excluded. Censor date was 27th July 2022. Patients were considered for referral to a tertiary transplantation center on a case by case basis; typically patients were under aged 65 years with advanced cardiac failure attributable to ATTR-CM and had little or no significant comorbidity.\u003C/p>\r\n\u003Cp class=\"mb0\">Patients were managed in accordance with the Declaration of Helsinki, the Declaration of Istanbul and the International Society for Heart and Lung Transplantation Statement on Transplant Ethics. Approval for retrospective analysis and publication of their anonymized data was obtained from the Royal Free London NHS Foundation Trust Ethics Committee (ref 06/Q0501/41).\u003C/p>\r\n\u003Ch3>Diagnosis\u003C/h3>\r\n\u003Cp class=\"mb0\">In each case, the diagnosis of ATTR-CM was established according to either validated non-biopsy criteria (\u003Ca href=\"#B14\">14\u003C/a>) and/or histological confirmation of cardiac ATTR amyloid deposits with imaging evidence of amyloid cardiomyopathy by echocardiogram and/or CMR. In brief, non-biopsy diagnostic criteria for ATTR-CM consist of echocardiographic and/or CMR imaging evidence suggestive of amyloid cardiomyopathy in together with a Perugini Grade 2 or 3 Tc-DPD scan and absence of a monoclonal gammopathy. Baseline/pre-transplant characteristics were established with biochemical tests which included full blood count, renal function, liver function tests, serum NT-proBNP and high sensitivity troponin T. Serum free light chains (retrospectively from a stored serum sample in patients transplanted before 2000), immunofixation and urine immunofixation were performed in all cases. NAC ATTR Stage was calculated on the basis of NT-proBNP concentration and MDRD eGFR, as previously published (\u003Ca href=\"#B15\">15\u003C/a>). Patients were followed routinely at NAC following CT with a full clinical evaluation, biochemical testing and echocardiography; selected cases underwent serial CMR and \u003Csup>99m\u003C/sup>Tc-3,3-Diphosphono-1-2-Propanodicarboxylic Acid (\u003Csup>99m\u003C/sup>Tc-DPD) scintigraphy.\u003C/p>\r\n\u003Ch3>Bone scintigraphy\u003C/h3>\r\n\u003Cp class=\"mb0\">Patients underwent radionuclide scintigraphy following an intravenous injection of approximately 700 MBq of \u003Csup>99m\u003C/sup>Tc-DPD. Whole body planar and single photon emission computed tomography with a low-dose, non-contrast CT scan (SPECT-CT) images of the heart were acquired 3 h post-injection using low energy, high resolution collimators. Cardiac uptake on all \u003Csup>99m\u003C/sup>Tc-DPD scans was categorized according to the Perugini grading system (\u003Ca href=\"#B16\">16\u003C/a>).\u003C/p>\r\n\u003Ch3>Echocardiography\u003C/h3>\r\n\u003Cp class=\"mb0\">Image acquisition and analysis was performed by independent, experienced and appropriately accredited echocardiographers in accordance with the latest European Association of Cardiovascular Imaging guidance (\u003Ca href=\"#B17\">17\u003C/a>).\u003C/p>\r\n\u003Ch3>Cardiac magnetic resonance\u003C/h3>\r\n\u003Cp class=\"mb0\">Cardiac magnetic resonance (CMR) was performed, after 2005, on a 1.5T scanner (Magnetom Aera, Siemens Healthcare, Erlangen, Germany). Localizers and cine imaging with steady state free precession sequences (SSFP) was performed. The contrast agent used was 0.1 mmol./kg of Gadoterate meglumine. Late gadolinium enhancement (LGE) imaging was acquired with magnitude inversion recovery (MAG-IR) and phase-sensitive inversion recovery (PSIR) sequence reconstruction with SSFP read-outs. T1 mapping was performed with the modified look-locker inversion (MOLLI) recovery sequence. T1 mapping was repeated 15 min post-contrast to produce extracellular volume (ECV) maps. All CMRs were analysed by independent consultant cardiologists.\u003C/p>\r\n\u003Ch3>Histology, proteomics, and immunohistochemistry\u003C/h3>\r\n\u003Cp class=\"mb0\">All biopsy samples were formalin-fixed and paraffin-embedded. Samples were stained with Congo red by the method of Putchtler, Sweat, and Levine (\u003Ca href=\"#B18\">18\u003C/a>). Amyloid fibril type was determined by immunohistochemical staining of amyloid deposits with a range of monospecific antibodies (\u003Ca href=\"#B19\">19\u003C/a>). Where necessary, laser microdissection and subsequent proteomic analysis definitively confirmed fibril type (\u003Ca href=\"#B20\">20\u003C/a>).\u003C/p>\r\n\u003Ch3>Genotyping\u003C/h3>\r\n\u003Cp class=\"mb0\">DNA extracted from blood was amplified by polymerase chain reaction assays and the whole coding region of the \u003Ci>TTR\u003C/i> gene was sequenced to identify any mutations.\u003C/p>\r\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Pre-transplant characteristics\u003C/h3>\r\n\u003Cp class=\"mb0\">A total of fourteen cardiac allograft recipients were identified. Patient and disease-related characteristics are shown in \u003Ca href=\"#T1\">Table 1\u003C/a>. Twelve of the fourteen recipients were male. Mean age at CT was 59 years, median time from diagnosis to CT was 22 months (IQR 13&#x2013;29 months). Nine patients had histological evidence of ATTR amyloid deposition on endomyocardial biopsy (EMB) accompanying characteristic cardiac imaging; the remaining patients fulfilled validated non-biopsy diagnostic criteria for ATTR-CM.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" name=\"table1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cb>Table 1.\u003C/b> Pre-transplant patient and disease characteristics among 14 patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who underwent cardiac transplantation.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Eleven patients had ATTRwt-CM and the remaining 3 had ATTRv-CM associated with the p.(Val142Ile), p.(Gly73Ala), and p.(Ser43Asn) variants respectively. One patient was NYHA functional class IV, eleven patients were NYHA functional class III and the remaining two cases were NYHA functional class II. Median (range) NT-proBNP concentration pre-transplant was 4,202 ng/L (1,057&#x2013;8,778 ng/L), median (range) left ventricular ejection fraction (LVEF) was 39% (27&#x2013;56%) and mean (IQR) interventricular septal thickness (IVSd) was 18 mm (14&#x2013;22 mm). At diagnosis, 8 patients had NAC ATTR stage II disease, 5 had stage I disease and the NAC ATTR stage was not evaluated in the remaining patient. It is notable that patients with NAC ATTR Stage III disease were likely excluded from consideration of CT on the basis of an estimated glomerular filtration rate (eGFR) of &#x003C; 45 ml/min (\u003Ca href=\"#B19\">19\u003C/a>).\u003C/p>\r\n\u003Ch3>Outcomes\u003C/h3>\r\n\u003Ch4>Survival\u003C/h4>\r\n\u003Cp class=\"mb0\">Post-transplant characteristics are shown in \u003Ca href=\"#T2\">Table 2\u003C/a>. Patients were followed up for a median (range) of 66 months (21&#x2013;233 months). At Censor, 10/14 (71%) patients were alive. Post-CT 1-year survival was 100%, 3-year survival was 92%, and 5-year survival was 90%. Overall estimated post-CT survival in ATTR-CM patients by Kaplan Meier analysis was 17.7 years (95% CI: 13&#x2013;21 years). Kaplan-Meier survival curves comparing patients who were and were not transplanted, the latter group stratified by NAC ATTR disease stage or by age &#x2264; 65 years at diagnosis, are shown in \u003Ca href=\"#F1\">Figure 1\u003C/a>. Kaplan Meier analysis showed substantially prolonged survival from diagnosis in patients who underwent CT compared to their non-transplanted counterparts regardless of age (\u003Ci>p\u003C/i> = 0.008) or disease severity (\u003Ci>p\u003C/i> &#x003C; 0.001) at the time of diagnosis.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" name=\"table2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cb>Table 2.\u003C/b> Outcomes, functional, and disease characteristics in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who underwent cardiac transplantation.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" name=\"figure1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cb>Figure 1.\u003C/b> Kaplan-Meier survival curves in 814 patients with transthyretin amyloid cardiomyopathy (ATTR-CM) stratified by NAC disease stage and compared to the cohort who underwent cardiac transplantation. Cardiac transplantation in this small cohort of selected patients was associated with a substantial prolongation of life expectancy measured from date of first diagnosis compared to patients who did not undergo cardiac transplantation (Transplant vs. NAC ATTR stage I, \u003Ci>p\u003C/i> &#x003C; 0.001; Transplant vs. NAC ATTR stage II, \u003Ci>p\u003C/i> &#x003C; 0.001; Transplant vs. NAC ATTR stage III, \u003Ci>p\u003C/i> &#x003C; 0.001) including the cohort of 71 NAC patients who were diagnosed with ATTR-CM under age 65 years (\u003Ci>p\u003C/i> = 0.008).\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">There were no reported episodes of significant post-operative bleeding. Two patients (patient 5 and 13) were successfully treated with intravenous steroids for allograft rejection in the immediate post-operative period. A further patient (Patient 4) required intravenous steroids for grade IIIA allograft rejection 8 months post CT. Two patients were successfully treated in hospital for cytomegalovirus infection during the immediate post-operative period.\u003C/p>\r\n\u003Cp class=\"mb0\">At the time of Censor, all but one surviving patient were NYHA functional class I. Patient 1 developed left ventricular hypertrophy 12 years following CT determined to be secondary to hypertensive heart disease. Notably, Tc-DPD scintigraphy in this patient 12 years post CT did not show evidence of cardiac allograft amyloid infiltration. The clinical course of non-surviving patients is available in further detail in \u003Ca href=\"#h10\">Supplementary material 1\u003C/a>.\u003C/p>\r\n\u003Ch4>Renal impairment\u003C/h4>\r\n\u003Cp class=\"mb0\">Post-CT renal impairment, including both acute kidney injury thought to be due to perioperative hypoperfusion, and progressive chronic kidney disease (CKD) was common and occurred in 8/14 CT recipients. Three patients required temporary post-operative hemodialysis with two recovering normal renal function, a further four were left with CKD. The final patient developed progressive CKD due to calcineurin inhibitor use 12 years after the CT which progressed to renal failure and hemodialysis dependence 19 years post-CT despite a switch from cyclosporin to sirolimus 5 years prior.\u003C/p>\r\n\u003Ch4>Recurrence of amyloid in the cardiac allograft\u003C/h4>\r\n\u003Cp class=\"mb0\">All patients were assessed regularly at their respective tertiary centers following CT. All patients were assessed for graft amyloid recurrence with Tc-DPD scintigraphy and/or endomyocardial biopsies in combination with CMR imaging. No patient developed recurrent amyloid in the cardiac allograft despite the fact that 12/14 patients did not receive disease-modifying therapy for amyloidosis. Two patients (patient 2 and patient 10), both of whom had ATTRv-CM were commenced on patisiran 210 months and 6 months post-CT respectively following development of mild ATTR-PN. It is notable that patient 2 demonstrated a progressive increase in soft tissue uptake on Tc-DPD scintigraphy post-CT, despite having an allograft EMB that was persistently free from amyloid, no cardiac uptake of Tc-DPD, and no evidence of cardiac amyloidosis on CMR over 17 years after CT (\u003Ca href=\"#F2\">Figure 2\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" name=\"figure2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cb>Figure 2.\u003C/b> Anterior whole body planar \u003Csup>99m\u003C/sup>Tc-DPD scintigraphy images in patient 2. Left and right panels were obtained seven and ten years post cardiac transplantation, respectively. Both scans are notable for the absence of cardiac uptake despite extensive soft tissue uptake which visibly increased across this 3 year interval.\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\r\n\u003Cp class=\"mb15\">Here we report multicentre experience in UK and Italy of CT in ATTR-CM. To our knowledge, this is the longest period of follow-up following CT reported to date in ATTR-CM and is the only such study that is multicentre. Both short-term and long-term outcomes were excellent with survival rates comparable to patients undergoing heart transplantation for non-amyloid indications. One-year survival in transplanted ATTR-CM patients was 100%, 3-year survival 92%, and 5-year survival 90%. The International Society for Heart and Lung Transplantation (ISHLT) registry report a 1-year survival rate post-CT of 84% (\u003Ca href=\"#B21\">21\u003C/a>). Between 2012 and 2020, the UK National Health Service transplant registry reported CT 1- and 5-year survival rates of 84 and 70% respectively. Whilst our cohort is highly selected and relatively small, Kaplan Meier analysis indicates vastly improved survival compared to unselected ATTR-CM patients, including a UK cohort of 71 un-transplanted patients diagnosed under age 65 years.\u003C/p>\r\n\u003Cp class=\"mb15\">Cardiac involvement is the most important determinant of mortality in systemic amyloidosis (\u003Ca href=\"#B3\">3\u003C/a>, \u003Ca href=\"#B22\">22\u003C/a>). For example, patients with p.(V50M)-associated ATTR-CM accompanying ATTR-PN carry a prognosis of approximately 5 years, compared to up to &#x223C;15 years in those with p.(V50M)-associated ATTR-PN alone (\u003Ca href=\"#B23\">23\u003C/a>). The role of &#x201C;standard&#x201D; heart failure therapies including ACE inhibitors, beta blockers and sacubitril/valsartan remains uncertain in ATTR-CM. Some authors argue these aggravate hemodynamic compromise and prohibit effective diuretic therapy (\u003Ca href=\"#B24\">24\u003C/a>). The role of SGLT2-inhibitors in ATTR-CM related heart failure is also unknown since ATTR-CM patients were excluded from relevant trials (\u003Ca href=\"#B25\">25\u003C/a>). Novel therapeutics such as patisiran, inotersen, and tafamidis, aimed specifically at modifying the inexorably progressive clinical course of ATTR amyloidosis are now in clinical use. However, whilst these agents may be effective at slowing or halting disease progression, there are no data to suggest that they are able to restore normal cardiac function in patients with established ATTR-CM (\u003Ca href=\"#B4\">4\u003C/a>&#x2013;\u003Ca href=\"#B6\">6\u003C/a>). Therefore, CT remains the only therapeutic option that has the potential to restore normal cardiac function and quality of life in patients with advanced ATTR-CM.\u003C/p>\r\n\u003Cp class=\"mb15\">The first case of CT in amyloid cardiomyopathy was reported in 1984 in a gentleman with cardiac AL amyloidosis (\u003Ca href=\"#B13\">13\u003C/a>, \u003Ca href=\"#B26\">26\u003C/a>). Subsequent reports of CT in cardiac amyloidosis highlighted recurrence of amyloid in the cardiac allograft and poor outcomes in comparison to patients undergoing CT for non-amyloid indications, and resulted in amyloid cardiomyopathy being considered an absolute contraindication to CT in some centers (\u003Ca href=\"#B27\">27\u003C/a>). However, some case series of CT in amyloid cardiomyopathy consider the condition as a single entity with no differentiation between amyloid types (\u003Ca href=\"#B8\">8\u003C/a>, \u003Ca href=\"#B11\">11\u003C/a>, \u003Ca href=\"#B12\">12\u003C/a>), despite the fact that the natural history, organ tropism and prognosis of systemic AL amyloidosis indicate a more aggressive and multi-system disease phenotype than that of ATTR amyloidosis (\u003Ca href=\"#B15\">15\u003C/a>, \u003Ca href=\"#B28\">28\u003C/a>). This stark difference in disease natural history coupled with the absence of detectable recurrence of ATTR amyloid in the cardiac allograft of any transplanted patient despite follow up of up to 19 years warrants consideration of the ATTR-CM indication for CT independently from that of cardiac AL amyloidosis. There is strong \u003Ci>in vivo\u003C/i> and \u003Ci>in vitro\u003C/i> evidence that presence of existing amyloid in a tissue promotes ongoing local amyloid deposition (\u003Ca href=\"#B29\">29\u003C/a>, \u003Ca href=\"#B30\">30\u003C/a>); this phenomenon, known as &#x201C;seeding,&#x201D; was evident in patient 2 who had ongoing accumulation of soft tissue amyloid following CT but did not develop amyloid in his cardiac allograft (confirmed by allograft biopsy 17 years post-CT) which was obviously amyloid na&#x00EF;ve at the time of transplantation. One can therefore take encouragement from our cohort that ongoing, unaltered hepatic TTR synthesis does not lead to recurrent amyloid in the cardiac allograft in the short or medium term.\u003C/p>\r\n\u003Cp class=\"mb15\">In patients with ATTRv amyloidosis, ATTR-PN accompanying ATTR-CM is a common and important clinical manifestation (\u003Ca href=\"#B2\">2\u003C/a>, \u003Ca href=\"#B4\">4\u003C/a>, \u003Ca href=\"#B23\">23\u003C/a>). Prior to the introduction of TTR suppressing and TTR stabilizing agents, liver transplantation to remove the circulating variant transthyretin, was the only available treatment for ATTR-PN. Whilst successful in patients with early-onset p.(V50M)-associated ATTRv amyloidosis who typically have ATTR-PN without ATTR-CM (\u003Ca href=\"#B31\">31\u003C/a>), liver transplantation in patients with established ATTRv-CM did not prevent ongoing deposition of wild-type ATTR amyloid deposits on top of the existing template of variant ATTR cardiac amyloid resulting in poor outcomes (\u003Ca href=\"#B32\">32\u003C/a>). As a result, combined liver and heart transplantation was performed in some patients with mixed ATTRv-CM and ATTRv-PN (\u003Ca href=\"#B33\">33\u003C/a>). However, with the advent of patisiran and inotersen, liver transplantation for ATTRv amyloidosis is now rarely undertaken. A small number of the &#x003E; 130 known amyloidogenic TTR variants are particularly associated with leptomeningeal ATTR amyloid deposition including p.(Thr69Pro), p.(Leu32Pro), p.(Tyr134Cys), and p.(Gly73Ala) (\u003Ca href=\"#B30\">30\u003C/a>, \u003Ca href=\"#B34\">34\u003C/a>&#x2013;\u003Ca href=\"#B36\">36\u003C/a>). Leptomeningeal ATTR amyloid deposits are composed of TTR protein which is synthesized in the choroid plexus rather than liver-derived circulating TTR protein such that patisiran and inotersen are ineffective at preventing neurological disease progression which carries a poor prognosis. Patients being considered for CT with these particular disease-causing variants need careful consideration, highlighted by the poor outcome in patient 4 in our cohort. Whilst patisiran and inotersen specifically target the liver (\u003Ca href=\"#B30\">30\u003C/a>, \u003Ca href=\"#B37\">37\u003C/a>), tafamidis has been shown to cross the blood brain barrier (\u003Ca href=\"#B37\">37\u003C/a>) and could conceivably stabilize TTR in the cerebrospinal fluid and thereby slow ongoing leptomeningeal ATTR amyloid deposition although this hypothesis remains speculative at the current time (\u003Ca href=\"#B6\">6\u003C/a>, \u003Ca href=\"#B38\">38\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Extracardiac ATTR amyloidosis is well-described in the literature (\u003Ca href=\"#B2\">2\u003C/a>). Whilst polyneuropathy, the hallmark phenotypic feature for which TTR gene silencers are licensed in ATTRv (\u003Ca href=\"#B4\">4\u003C/a>, \u003Ca href=\"#B5\">5\u003C/a>), is unequivocally caused by amyloid deposits it remains uncertain to what extent amyloid deposits contribute to other common organ manifestations in patients with ATTR amyloidosis such as gastrointestinal disturbance, lumbar canal stenosis and joint pains despite their almost universal presence in the relevant tissue. A recent study reported development of extra-cardiac disease manifestations following CT in patients with ATTR-CM (\u003Ca href=\"#B39\">39\u003C/a>) which is entirely consistent with our findings in which two patients were diagnosed with amyloid polyneuropathy 210 and 6 months post CT. However, given the recent availability of TTR gene silencers that effectively halt the progression of ATTR-PN, we would argue that concerns surrounding the possible development of ATTR-PN post CT should not preclude suitable ATTR-CM patients from undergoing CT. With regular monitoring, symptoms of ATTR-PN can be detected at an early stage, and where indicated, TTR gene silencers can be introduced in a timely manner. The orthopedic symptoms which appear to be over-represented in patients with ATTR amyloidosis, such as lumbar canal stenosis and carpal tunnel syndrome, can be effectively alleviated by surgical or non-surgical intervention. Given that cardiac allograft function is typically preserved in ATTR-CM post-CT, such patients are usually able to tolerate general anesthesia from a cardiac perspective.\u003C/p>\r\n\u003Cp class=\"mb15\">Our study has limitations. Pre-operative invasive physiological data is not readily available due to the fact transplantation was undertaken in institutions external to the individual amyloidosis centers. Whilst multicentre, the cohort is small and highly selected and we acknowledge the limitations of statistical analyses. Additionally, since disease-modifying therapies have only been available for the past 3&#x2013;4 years, we are unable to report on outcomes with their long-term use following CT; however, the absence of amyloid recurrence within the cardiac allograft argues against the need for administration of such therapies to protect the cardiac allograft after CT in patients with ATTRwt-CM.\u003C/p>\r\n\u003Cp class=\"mb0\">In conclusion, CT in selected patients with ATTR-CM is a robust intervention which restores quality of life and prolongs patient survival. The risk of cardiac allograft amyloid recurrence in the short and medium term appears to be negligible. Longer term follow-up studies will be required to determine whether administration of disease-modifying therapies post-CT provides any additional clinical benefit in patients with isolated ATTR-CM. The authors advise caution when considering the suitability of patients with ATTRv-CM for CT who carry TTR mutations which are known to be associated with important leptomeningeal amyloidosis.\u003C/p>\r\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Data availability statement\u003C/h2>\r\n\u003Cp class=\"mb0\">The anonymized raw data supporting the conclusions of this article can be made available by the authors upon reasonable request.\u003C/p>\r\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Author contributions\u003C/h2>\r\n\u003Cp class=\"mb0\">YR and AP conceived the study, carried out data collection, analysis, and manuscript preparation. CD carried out data collection and manuscript review. RP, AI, MR, AM, StL, LC, TR, SR, JaG, DR, IB, NK, DH, HL, AW, WM, SeL, CC, CW, LV, and AM-N contributed to data analysis and manuscript review and editing. MM, GS, UL, and PH contributed with data collection, manuscript preparation, and review. MF and JuG oversaw the study design, data collection, manuscript preparation, review, and final approval. All authors contributed to the article and approved the submitted version.\u003C/p>\r\n\u003Ca id=\"h17\" name=\"h17\">\u003C/a>\u003Ch2>Funding\u003C/h2>\r\n\u003Cp class=\"mb0\">MF reports grant support from the British Heart Foundation.\u003C/p>\r\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Conflict of interest\u003C/h2>\r\n\u003Cp class=\"mb15\">DH receives speaker fees from Akcea Therapeutics Ltd., and Alnylam UK. SeL receives support fees from Abiomed. MF has received consulting income from Intellia, Novo-Nordisk, Pfizer, Eidos, Prothena, Akcea, Alnylam, Caleum, Alexion, Jennsen and her institution has received clinical trial fundings from Pfizer, Eidos, and Alnylam. JuG receives consulting fees from Alnyman, Ionis, Eidos, Intellia, Pfizer, and ATTRalus.\u003C/p>\r\n\u003Cp class=\"mb0\">The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\r\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Publisher&#x2019;s note\u003C/h2>\r\n\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\r\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Supplementary material\u003C/h2>\r\n\u003Cp class=\"mb0\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fcvm.2022.1075806/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fcvm.2022.1075806/full#supplementary-material\u003C/a>\u003C/p>\r\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Abbreviations\u003C/h2>\r\n\u003Cp class=\"mb0\">TTR, transthyretin; ATTR, transthyretin amyloid; ATTR-CM, transthyretin amyloid cardiomyopathy; CT, cardiac transplantation; ATTRv, variant/hereditary transthyretin amyloid; ATTRwt, wild type transthyretin amyloid; ATTR-PN, transthyretin amyloid polyneuropathy; Tc-DPD, Tc-3,3-Diphosphono-1-2-Propanodicarboxylic Acid; CMR, cardiac magnetic resonance; SSFP, steady state free precession; LGE, late gadolinium enhancement; MAG-IR, magnitude inversion recovery; PSIR, phase sensitive inversion recovery; MOLLI, modified look-locker inversion; ECV, extracellular volume; LVEF, left ventricular ejection fraction; IVSd, interventricular septal thickness in diastole; eGFR, estimated glomerular filtration rate; ISHLT, international society for heart and lung transplantation; LVH, left ventricular hypertrophy; CMV, cytomegalovirus.\u003C/p>\r\n\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>References\u003C/h2>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a>1. Razvi Y, Patel R, Fontana M, Gillmore J. Cardiac amyloidosis: a review of current imaging techniques. \u003Ci>Front Cardiovasc Med.\u003C/i> (2021) 8:751293. doi: 10.3389/fcvm.2021.751293\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34957240\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fcvm.2021.751293\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+amyloidosis%3A+a+review+of+current+imaging+techniques%2E&#x0026;journal=Front+Cardiovasc+Med%2E&#x0026;author=Razvi+Y&#x0026;author=Patel+R&#x0026;author=Fontana+M&#x0026;author=Gillmore+J&#x0026;publication_year=2021&#x0026;volume=8&#x0026;issue=751293\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a>2. Wechalekar A, Gillmore J, Hawkins P. Systemic amyloidosis. \u003Ci>Lancet.\u003C/i> (2016) 387:2641&#x2013;54. doi: 10.1016/S0140-6736(15)01274-X\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1016/S0140-6736(15)01274-X\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Systemic+amyloidosis%2E&#x0026;journal=Lancet%2E&#x0026;author=Wechalekar+A&#x0026;author=Gillmore+J&#x0026;author=Hawkins+P&#x0026;publication_year=2016&#x0026;volume=387&#x0026;pages=2641&#x2013;54\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a>3. Martinez-Naharro A, Hawkins P, Fontana M. Cardiac amyloidosis. \u003Ci>Clin Med J R Coll Phys Lond.\u003C/i> (2018) 18:s30&#x2013;5. doi: 10.7861/clinmedicine.18-2-s30\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29700090\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.7861/clinmedicine.18-2-s30\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+amyloidosis%2E&#x0026;journal=Clin+Med+J+R+Coll+Phys+Lond%2E&#x0026;author=Martinez-Naharro+A&#x0026;author=Hawkins+P&#x0026;author=Fontana+M&#x0026;publication_year=2018&#x0026;volume=18&#x0026;pages=s30&#x2013;5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a>4. Adams D, Gonzalez-Duarte A, O&#x2019;Riordan W, Yang C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:11&#x2013;21.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Patisiran%2C+an+RNAi+therapeutic%2C+for+hereditary+transthyretin+amyloidosis%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Adams+D&#x0026;author=Gonzalez-Duarte+A&#x0026;author=O&#x2019;Riordan+W&#x0026;author=Yang+C&#x0026;author=Ueda+M&#x0026;author=Kristen+AV&#x0026;publication_year=2018&#x0026;volume=379&#x0026;pages=11&#x2013;21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a>5. Benson M, Waddington-Cruz M, Berk J, Polydefkis M, Dyck P, Wang A, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:22&#x2013;31.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Inotersen+treatment+for+patients+with+hereditary+transthyretin+amyloidosis%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Benson+M&#x0026;author=Waddington-Cruz+M&#x0026;author=Berk+J&#x0026;author=Polydefkis+M&#x0026;author=Dyck+P&#x0026;author=Wang+A&#x0026;publication_year=2018&#x0026;volume=379&#x0026;pages=22&#x2013;31\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a>6. Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:1007&#x2013;16.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Tafamidis+treatment+for+patients+with+transthyretin+amyloid+cardiomyopathy%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Maurer+M&#x0026;author=Schwartz+J&#x0026;author=Gundapaneni+B&#x0026;author=Elliott+P&#x0026;author=Merlini+G&#x0026;author=Waddington-Cruz+M&#x0026;publication_year=2018&#x0026;volume=379&#x0026;pages=1007&#x2013;16\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a>7. Gillmore J, Gane E, Taubel J, Kao J, Fontana M, Maitland M, et al. CRISPR-Cas9 \u003Ci>in vivo\u003C/i> gene editing for transthyretin amyloidosis. \u003Ci>N Engl J Med.\u003C/i> (2021) 385:493&#x2013;502. doi: 10.1056/NEJMoa2107454\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34215024\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa2107454\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=CRISPR-Cas9+in+vivo+gene+editing+for+transthyretin+amyloidosis%2E&#x0026;journal=N+Engl+J+Med%2E&#x0026;author=Gillmore+J&#x0026;author=Gane+E&#x0026;author=Taubel+J&#x0026;author=Kao+J&#x0026;author=Fontana+M&#x0026;author=Maitland+M&#x0026;publication_year=2021&#x0026;volume=385&#x0026;pages=493&#x2013;502\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a>8. Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. \u003Ci>Heart Fail Rev.\u003C/i> (2017) 22:317&#x2013;27. doi: 10.1007/s10741-017-9601-z\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28281017\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10741-017-9601-z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Heart+transplantation+in+cardiac+amyloidosis%2E&#x0026;journal=Heart+Fail+Rev%2E&#x0026;author=Sousa+M&#x0026;author=Monohan+G&#x0026;author=Rajagopalan+N&#x0026;author=Grigorian+A&#x0026;author=Guglin+M&#x0026;publication_year=2017&#x0026;volume=22&#x0026;pages=317&#x2013;27\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a>9. Carvalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. \u003Ci>Liver Transpl.\u003C/i> (2015) 21:282&#x2013;92. doi: 10.1002/lt.24058\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25482846\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/lt.24058\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Liver+transplantation+in+transthyretin+amyloidosis%3A+issues+and+challenges%2E&#x0026;journal=Liver+Transpl%2E&#x0026;author=Carvalho+A&#x0026;author=Rocha+A&#x0026;author=Lobato+L&#x0026;publication_year=2015&#x0026;volume=21&#x0026;pages=282&#x2013;92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a>10. Nardo B, Beltempo P, Bertelli R, Montalti R, Vivarelli M, Cescon M, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. \u003Ci>Transplant Proc.\u003C/i> (2004) 36:645&#x2013;7. doi: 10.1016/j.transproceed.2004.03.076\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15110620\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.transproceed.2004.03.076\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Combined+heart+and+liver+transplantation+in+four+adults+with+familial+amyloidosis%3A+experience+of+a+single+center%2E&#x0026;journal=Transplant+Proc%2E&#x0026;author=Nardo+B&#x0026;author=Beltempo+P&#x0026;author=Bertelli+R&#x0026;author=Montalti+R&#x0026;author=Vivarelli+M&#x0026;author=Cescon+M&#x0026;publication_year=2004&#x0026;volume=36&#x0026;pages=645&#x2013;7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a>11. Davis M, Kale P, Liedtke M, Schrier S, Arai S, Wheeler M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. \u003Ci>Am J Transpl.\u003C/i> (2015) 15:650&#x2013;8.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Outcomes+after+heart+transplantation+for+amyloid+cardiomyopathy+in+the+modern+era%2E&#x0026;journal=Am+J+Transpl%2E&#x0026;author=Davis+M&#x0026;author=Kale+P&#x0026;author=Liedtke+M&#x0026;author=Schrier+S&#x0026;author=Arai+S&#x0026;author=Wheeler+M&#x0026;publication_year=2015&#x0026;volume=15&#x0026;pages=650&#x2013;8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a>12. Kpodonu J, Massad M, Caines A, Geha A. Outcome of heart transplantation in patients with amyloid cardiomyopathy. \u003Ci>J Heart Lung Transplant.\u003C/i> (2005) 24:1763&#x2013;5. doi: 10.1016/j.healun.2004.08.025\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16297778\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.healun.2004.08.025\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Outcome+of+heart+transplantation+in+patients+with+amyloid+cardiomyopathy%2E&#x0026;journal=J+Heart+Lung+Transplant%2E&#x0026;author=Kpodonu+J&#x0026;author=Massad+M&#x0026;author=Caines+A&#x0026;author=Geha+A&#x0026;publication_year=2005&#x0026;volume=24&#x0026;pages=1763&#x2013;5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a>13. Dubrey S, Burke M, Hawkins P, Banner N. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. \u003Ci>J Heart Lung Transpl.\u003C/i> (2004) 23:1142&#x2013;53. doi: 10.1016/j.healun.2003.08.027\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15477107\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.healun.2003.08.027\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+transplantation+for+amyloid+heart+disease%3A+the+United+Kingdom+experience%2E&#x0026;journal=J+Heart+Lung+Transpl%2E&#x0026;author=Dubrey+S&#x0026;author=Burke+M&#x0026;author=Hawkins+P&#x0026;author=Banner+N&#x0026;publication_year=2004&#x0026;volume=23&#x0026;pages=1142&#x2013;53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a>14. Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. \u003Ci>Circulation.\u003C/i> (2016) 133:2404&#x2013;12.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Nonbiopsy+diagnosis+of+cardiac+transthyretin+amyloidosis%2E&#x0026;journal=Circulation%2E&#x0026;author=Gillmore+J&#x0026;author=Maurer+M&#x0026;author=Falk+R&#x0026;author=Merlini+G&#x0026;author=Damy+T&#x0026;author=Dispenzieri+A&#x0026;publication_year=2016&#x0026;volume=133&#x0026;pages=2404&#x2013;12\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a>15. Gillmore J, Damy T, Fontana M, Hutchinson M, Lachmann H, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. \u003Ci>Eur Heart J.\u003C/i> (2018) 39:2799&#x2013;806. doi: 10.1093/eurheartj/ehx589\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29048471\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehx589\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+new+staging+system+for+cardiac+transthyretin+amyloidosis%2E&#x0026;journal=Eur+Heart+J%2E&#x0026;author=Gillmore+J&#x0026;author=Damy+T&#x0026;author=Fontana+M&#x0026;author=Hutchinson+M&#x0026;author=Lachmann+H&#x0026;author=Martinez-Naharro+A&#x0026;publication_year=2018&#x0026;volume=39&#x0026;pages=2799&#x2013;806\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a>16. Perugini E, Guidalotti P, Salvi F, Cooke R, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. \u003Ci>J Am Coll Cardiol.\u003C/i> (2005) 46:1076&#x2013;84. doi: 10.1016/j.jacc.2005.05.073\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16168294\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jacc.2005.05.073\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Noninvasive+etiologic+diagnosis+of+cardiac+amyloidosis+using+99mTc-3%2C3-diphosphono-1%2C2-propanodicarboxylic+acid+scintigraphy%2E&#x0026;journal=J+Am+Coll+Cardiol%2E&#x0026;author=Perugini+E&#x0026;author=Guidalotti+P&#x0026;author=Salvi+F&#x0026;author=Cooke+R&#x0026;author=Pettinato+C&#x0026;author=Riva+L&#x0026;publication_year=2005&#x0026;volume=46&#x0026;pages=1076&#x2013;84\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a>17. Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. \u003Ci>J Am Soc Echocardiogr.\u003C/i> (2015) 28:1&#x2013;39.e14.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Recommendations+for+cardiac+chamber+quantification+by+echocardiography+in+adults%3A+an+update+from+the+American+society+of+echocardiography+and+the+European+association+of+cardiovascular+imaging%2E&#x0026;journal=J+Am+Soc+Echocardiogr%2E&#x0026;author=Lang+R&#x0026;author=Badano+L&#x0026;author=Mor-Avi+V&#x0026;author=Afilalo+J&#x0026;author=Armstrong+A&#x0026;author=Ernande+L&#x0026;publication_year=2015&#x0026;volume=28&#x0026;pages=1&#x2013;39.e14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a>18. Amyloid B, Puchtler H, Sweat F, Levine M. On the binding of congo red by amyloid. \u003Ci>J Histochem Cytochem.\u003C/i> (2017) 10:355&#x2013;64.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=On+the+binding+of+congo+red+by+amyloid%2E&#x0026;journal=J+Histochem+Cytochem%2E&#x0026;author=Amyloid+B&#x0026;author=Puchtler+H&#x0026;author=Sweat+F&#x0026;author=Levine+M&#x0026;publication_year=2017&#x0026;volume=10&#x0026;pages=355&#x2013;64\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a>19. Rezk T, Gilbertson J, Mangione P, Rowczenio D, Rendell N, Canetti D, et al. The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. \u003Ci>J Pathol Clin Res.\u003C/i> (2019) 5:145&#x2013;53. doi: 10.1002/cjp2.126\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30740936\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cjp2.126\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+complementary+role+of+histology+and+proteomics+for+diagnosis+and+typing+of+systemic+amyloidosis%2E&#x0026;journal=J+Pathol+Clin+Res%2E&#x0026;author=Rezk+T&#x0026;author=Gilbertson+J&#x0026;author=Mangione+P&#x0026;author=Rowczenio+D&#x0026;author=Rendell+N&#x0026;author=Canetti+D&#x0026;publication_year=2019&#x0026;volume=5&#x0026;pages=145&#x2013;53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a>20. Vrana J, Gamez J, Madden B, Theis J, Bergen H, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. \u003Ci>Blood.\u003C/i> (2009) 114:4957&#x2013;9. doi: 10.1182/blood-2009-07-230722\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19797517\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1182/blood-2009-07-230722\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Classification+of+amyloidosis+by+laser+microdissection+and+mass+spectrometry-based+proteomic+analysis+in+clinical+biopsy+specimens%2E&#x0026;journal=Blood%2E&#x0026;author=Vrana+J&#x0026;author=Gamez+J&#x0026;author=Madden+B&#x0026;author=Theis+J&#x0026;author=Bergen+H&#x0026;author=Dogan+A&#x0026;publication_year=2009&#x0026;volume=114&#x0026;pages=4957&#x2013;9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a>21. Lund L, Edwards L, Kucheryavaya A, Dipchand A, Benden C, Christie J, et al. The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report&#x2013;2013; focus theme: age. \u003Ci>J Heart Lung Transplant.\u003C/i> (2013) 32:951&#x2013;64. doi: 10.1016/j.healun.2013.08.006\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24054804\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.healun.2013.08.006\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=The+registry+of+the+international+society+for+heart+and+lung+transplantation%3A+thirtieth+official+adult+heart+transplant+report&#x2013;2013;+focus+theme%3A+age%2E&#x0026;journal=J+Heart+Lung+Transplant%2E&#x0026;author=Lund+L&#x0026;author=Edwards+L&#x0026;author=Kucheryavaya+A&#x0026;author=Dipchand+A&#x0026;author=Benden+C&#x0026;author=Christie+J&#x0026;publication_year=2013&#x0026;volume=32&#x0026;pages=951&#x2013;64\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a>22. Lane T, Fontana M, Martinez-Naharro A, Quarta C, Whelan C, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. \u003Ci>Circulation.\u003C/i> (2019) 140:16&#x2013;26.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Natural+history%2C+quality+of+life%2C+and+outcome+in+cardiac+transthyretin+amyloidosis%2E&#x0026;journal=Circulation%2E&#x0026;author=Lane+T&#x0026;author=Fontana+M&#x0026;author=Martinez-Naharro+A&#x0026;author=Quarta+C&#x0026;author=Whelan+C&#x0026;author=Petrie+A&#x0026;publication_year=2019&#x0026;volume=140&#x0026;pages=16&#x2013;26\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a>23. Suhr O, Larsson M, Ericzon B, Wilczek H. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP world transplant registry. \u003Ci>Transplantation.\u003C/i> (2016) 100:373&#x2013;81. doi: 10.1097/TP.0000000000001021\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26656838\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/TP.0000000000001021\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Survival+after+transplantation+in+patients+with+mutations+other+than+Val30Met%3A+extracts+from+the+FAP+world+transplant+registry%2E&#x0026;journal=Transplantation%2E&#x0026;author=Suhr+O&#x0026;author=Larsson+M&#x0026;author=Ericzon+B&#x0026;author=Wilczek+H&#x0026;publication_year=2016&#x0026;volume=100&#x0026;pages=373&#x2013;81\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a>24. Selvanayagam J, Hawkins P, Paul B, Myerson S, Neubauer S. Evaluation and management of the cardiac amyloidosis. \u003Ci>J Am Coll Cardiol.\u003C/i> (2007) 50:2101&#x2013;10.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Evaluation+and+management+of+the+cardiac+amyloidosis%2E&#x0026;journal=J+Am+Coll+Cardiol%2E&#x0026;author=Selvanayagam+J&#x0026;author=Hawkins+P&#x0026;author=Paul+B&#x0026;author=Myerson+S&#x0026;author=Neubauer+S&#x0026;publication_year=2007&#x0026;volume=50&#x0026;pages=2101&#x2013;10\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a>25. Cardoso R, Graffunder F, Ternes C, Fernandes A, Rocha AV, Fernandes G, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. \u003Ci>EClinicalMedicine.\u003C/i> (2021) 36:100933. doi: 10.1016/j.eclinm.2021.100933\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34308311\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.eclinm.2021.100933\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=SGLT2+inhibitors+decrease+cardiovascular+death+and+heart+failure+hospitalizations+in+patients+with+heart+failure%3A+a+systematic+review+and+meta-analysis%2E&#x0026;journal=EClinicalMedicine%2E&#x0026;author=Cardoso+R&#x0026;author=Graffunder+F&#x0026;author=Ternes+C&#x0026;author=Fernandes+A&#x0026;author=Rocha+AV&#x0026;author=Fernandes+G&#x0026;publication_year=2021&#x0026;volume=36&#x0026;issue=100933\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a>26. Hall R, Hawkins PN. Grand rounds-hammersmith hospital cardiac transplantation for AL amyloidosis. \u003Ci>BMJ.\u003C/i> (1994) 309:1135. doi: 10.1136/bmj.309.6962.1135\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7987109\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/bmj.309.6962.1135\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Grand+rounds-hammersmith+hospital+cardiac+transplantation+for+AL+amyloidosis%2E&#x0026;journal=BMJ%2E&#x0026;author=Hall+R&#x0026;author=Hawkins+PN&#x0026;publication_year=1994&#x0026;volume=309&#x0026;issue=1135\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a>27. Macdonald P, Peter Macdonald C. Heart transplantation: who should be considered and when? \u003Ci>Intern Med J.\u003C/i> (2008) 38:911&#x2013;7. doi: 10.1111/j.1445-5994.2008.01833.x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19120548\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1445-5994.2008.01833.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Heart+transplantation%3A+who+should+be+considered+and+when%B4&#x0026;journal=Intern+Med+J%2E&#x0026;author=Macdonald+P&#x0026;author=Peter+Macdonald+C&#x0026;publication_year=2008&#x0026;volume=38&#x0026;pages=911&#x2013;7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a>28. Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. \u003Ci>Heart Fail Rev.\u003C/i> (2015) 20:155&#x2013;62. doi: 10.1007/s10741-014-9464-5\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25447844\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10741-014-9464-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Natural+history+and+therapy+of+AL+cardiac+amyloidosis%2E&#x0026;journal=Heart+Fail+Rev%2E&#x0026;author=Grogan+M&#x0026;author=Dispenzieri+A&#x0026;publication_year=2015&#x0026;volume=20&#x0026;pages=155&#x2013;62\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a>29. Pepys M. Amyloidosis. \u003Ci>Annu Rev Med.\u003C/i> (2006) 57:223&#x2013;41. doi: 10.1146/annurev.med.57.121304.131243\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16409147\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1146/annurev.med.57.121304.131243\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Amyloidosis%2E&#x0026;journal=Annu+Rev+Med%2E&#x0026;author=Pepys+M&#x0026;publication_year=2006&#x0026;volume=57&#x0026;pages=223&#x2013;41\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a>30. Douglass C, Suvarna K, Reilly M, Hawkins P, Hadjivassiliou M. A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia. \u003Ci>J Neurol Neurosurg Psychiatry.\u003C/i> (2007) 78:193. doi: 10.1136/jnnp.2006.093500\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16971399\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jnnp.2006.093500\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+novel+amyloidogenic+transthyretin+variant%2C+Gly53Ala%2C+associated+with+intermittent+headaches+and+ataxia%2E&#x0026;journal=J+Neurol+Neurosurg+Psychiatry%2E&#x0026;author=Douglass+C&#x0026;author=Suvarna+K&#x0026;author=Reilly+M&#x0026;author=Hawkins+P&#x0026;author=Hadjivassiliou+M&#x0026;publication_year=2007&#x0026;volume=78&#x0026;issue=193\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a>31. Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. \u003Ci>Curr Opin Neurol.\u003C/i> (2012) 25:564&#x2013;72. doi: 10.1097/WCO.0b013e328357bdf6\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22941262\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/WCO.0b013e328357bdf6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Amyloid+neuropathies%2E&#x0026;journal=Curr+Opin+Neurol%2E&#x0026;author=Adams+D&#x0026;author=Lozeron+P&#x0026;author=Lacroix+C&#x0026;publication_year=2012&#x0026;volume=25&#x0026;pages=564&#x2013;72\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a>32. Sattianayagam P, Hahn A, Whelan C, Gibbs S, Pinney J, Stangou A, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. \u003Ci>Eur Heart J.\u003C/i> (2012) 33:1120&#x2013;7. doi: 10.1093/eurheartj/ehr383\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21992998\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/eurheartj/ehr383\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Cardiac+phenotype+and+clinical+outcome+of+familial+amyloid+polyneuropathy+associated+with+transthyretin+alanine+60+variant%2E&#x0026;journal=Eur+Heart+J%2E&#x0026;author=Sattianayagam+P&#x0026;author=Hahn+A&#x0026;author=Whelan+C&#x0026;author=Gibbs+S&#x0026;author=Pinney+J&#x0026;author=Stangou+A&#x0026;publication_year=2012&#x0026;volume=33&#x0026;pages=1120&#x2013;7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a>33. Nelson L, Penninga L, Sander K, Hansen P, Villadsen G, Rasmussen A, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. \u003Ci>Clin Transplant.\u003C/i> (2013) 27:203&#x2013;9. doi: 10.1111/ctr.12053\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23278526\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/ctr.12053\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Long-term+outcome+in+patients+treated+with+combined+heart+and+liver+transplantation+for+familial+amyloidotic+cardiomyopathy%2E&#x0026;journal=Clin+Transplant%2E&#x0026;author=Nelson+L&#x0026;author=Penninga+L&#x0026;author=Sander+K&#x0026;author=Hansen+P&#x0026;author=Villadsen+G&#x0026;author=Rasmussen+A&#x0026;publication_year=2013&#x0026;volume=27&#x0026;pages=203&#x2013;9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a>34. Ueno S, Uemichi T, Yorifuji S, Tarui S. A novel variant of transthyretin (Tyr114 to Cys) deduced from the nucleotide sequences of gene fragments from familial amyloidotic polyneuropathy in Japanese sibling cases. \u003Ci>Biochem Biophys Res Commun.\u003C/i> (1990) 169:143&#x2013;7. doi: 10.1016/0006-291x(90)91445-x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2161654\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/0006-291x(90)91445-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+novel+variant+of+transthyretin+%28Tyr114+to+Cys%29+deduced+from+the+nucleotide+sequences+of+gene+fragments+from+familial+amyloidotic+polyneuropathy+in+Japanese+sibling+cases%2E&#x0026;journal=Biochem+Biophys+Res+Commun%2E&#x0026;author=Ueno+S&#x0026;author=Uemichi+T&#x0026;author=Yorifuji+S&#x0026;author=Tarui+S&#x0026;publication_year=1990&#x0026;volume=169&#x0026;pages=143&#x2013;7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a>35. Brett M, Persey M, Reilly M, Revesz T, Booth D, Booth S, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. \u003Ci>Brain.\u003C/i> (1999) 122(Pt. 2):183&#x2013;90. doi: 10.1093/brain/122.2.183\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10071047\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/brain/122.2.183\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Transthyretin+Leu12Pro+is+associated+with+systemic%2C+neuropathic+and+leptomeningeal+amyloidosis%2E&#x0026;journal=Brain%2E&#x0026;author=Brett+M&#x0026;author=Persey+M&#x0026;author=Reilly+M&#x0026;author=Revesz+T&#x0026;author=Booth+D&#x0026;author=Booth+S&#x0026;publication_year=1999&#x0026;volume=122(Pt. 2)&#x0026;pages=183&#x2013;90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a>36. Nakagawa K, Sheikh S, Snuderl M, Frosch M, Greenberg SM. A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. \u003Ci>J Neurol Sci.\u003C/i> (2008) 272:186&#x2013;90. doi: 10.1016/j.jns.2008.05.014\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18579156\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jns.2008.05.014\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=A+new+Thr49Pro+transthyretin+gene+mutation+associated+with+leptomeningeal+amyloidosis%2E&#x0026;journal=J+Neurol+Sci%2E&#x0026;author=Nakagawa+K&#x0026;author=Sheikh+S&#x0026;author=Snuderl+M&#x0026;author=Frosch+M&#x0026;author=Greenberg+SM&#x0026;publication_year=2008&#x0026;volume=272&#x0026;pages=186&#x2013;90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a>37. Monteiro C, Martins da Silva A, Ferreira N, Mesgarzadeh J, Novais M, Coelho T, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. \u003Ci>Amyloid.\u003C/i> (2018) 25:120&#x2013;8. doi: 10.1080/13506129.2018.1479249\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29993288\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/13506129.2018.1479249\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Cerebrospinal+fluid+and+vitreous+body+exposure+to+orally+administered+tafamidis+in+hereditary+ATTRV30M+%28p%2ETTRV50M%29+amyloidosis+patients%2E&#x0026;journal=Amyloid%2E&#x0026;author=Monteiro+C&#x0026;author=Martins+da+Silva+A&#x0026;author=Ferreira+N&#x0026;author=Mesgarzadeh+J&#x0026;author=Novais+M&#x0026;author=Coelho+T&#x0026;publication_year=2018&#x0026;volume=25&#x0026;pages=120&#x2013;8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a>38. Coelho T, Maia L, da Silva A, Cruz M, Plant&#x00E9;-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. \u003Ci>Neurology.\u003C/i> (2012) 79:785.\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Tafamidis+for+transthyretin+familial+amyloid+polyneuropathy%3A+a+randomized%2C+controlled+trial%2E&#x0026;journal=Neurology%2E&#x0026;author=Coelho+T&#x0026;author=Maia+L&#x0026;author=da+Silva+A&#x0026;author=Cruz+M&#x0026;author=Plant&#x00E9;-Bordeneuve+V&#x0026;author=Lozeron+P&#x0026;publication_year=2012&#x0026;volume=79&#x0026;issue=785\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em;\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a>39. Griffin J, Baughan E, Rosenblum H, Clerkin K, Fried J, Raikhelkar J, et al. Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. \u003Ci>J Heart Lung Transpl.\u003C/i> (2022) 41:199&#x2013;207. doi: 10.1016/j.healun.2021.10.007\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/34922822\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.healun.2021.10.007\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?&#x0026;title=Surveillance+for+disease+progression+of+transthyretin+amyloidosis+after+heart+transplantation+in+the+era+of+novel+disease+modifying+therapies%2E&#x0026;journal=J+Heart+Lung+Transpl%2E&#x0026;author=Griffin+J&#x0026;author=Baughan+E&#x0026;author=Rosenblum+H&#x0026;author=Clerkin+K&#x0026;author=Fried+J&#x0026;author=Raikhelkar+J&#x0026;publication_year=2022&#x0026;volume=41&#x0026;pages=199&#x2013;207\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\r\n\u003Cdiv class=\"AbstractSummary\">\r\n\u003Cp>\u003Cspan>Keywords\u003C/span>: amyloid, transplant, heart failure, TTR&#x2013;transthyretin, outcome\u003C/p>\r\n\u003Cp>\u003Cspan>Citation:\u003C/span> Razvi Y, Porcari A, Di Nora C, Patel RK, Ioannou A, Rauf MU, Masi A, Law S, Chacko L, Rezk T, Ravichandran S, Gilbertson J, Rowczenio D, Blakeney IJ, Kaza N, Hutt DF, Lachmann H, Wechalekar A, Moody W, Lim S, Chue C, Whelan C, Venneri L, Martinez-Naharro A, Merlo M, Sinagra G, Livi U, Hawkins P, Fontana M and Gillmore JD (2023) Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience. \u003Ci>Front. Cardiovasc. Med.\u003C/i> 9:1075806. doi: 10.3389/fcvm.2022.1075806\u003C/p>\r\n\u003Cp id=\"timestamps\">\r\n\u003Cspan>Received:\u003C/span> 20 October 2022; \u003Cspan>Accepted:\u003C/span> 23 December 2022;\u003Cbr>\u003Cspan>Published:\u003C/span> 19 January 2023.\u003C/p>\r\n\u003Cdiv>\r\n\u003Cp>Edited by:\u003C/p>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/1111136/overview\">Giovanni Quarta\u003C/a>, Papa Giovanni XXIII Hospital, Italy\u003C/div>\r\n\u003Cdiv>\r\n\u003Cp>Reviewed by:\u003C/p>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/1282987/overview\">Beatrice Musumeci\u003C/a>, Sapienza University of Rome, Italy\u003Cbr>\r\n\u003Ca href=\"https://loop.frontiersin.org/people/1655841/overview\">Yasuhiro Izumiya\u003C/a>, Osaka City University, Japan\u003C/div>\r\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x00A9; 2023 Razvi, Porcari, Di Nora, Patel, Ioannou, Rauf, Masi, Law, Chacko, Rezk, Ravichandran, Gilbertson, Rowczenio, Blakeney, Kaza, Hutt, Lachmann, Wechalekar, Moody, Lim, Chue, Whelan, Venneri, Martinez-Naharro, Merlo, Sinagra, Livi, Hawkins, Fontana and Gillmore. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\r\n\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Julian D. Gillmore, \u003Cimg src=\"https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/email.jpg\" alt=\"www.frontiersin.org\" > \u003Ca id=\"encmail\">ai5naWxsbW9yZUB1Y2wuYWMudWs=\u003C/a>\u003C/p>\r\n\u003Cp>\u003Csup>&#x2020;\u003C/sup>These authors have contributed equally to this work and share first authorship\u003C/p>\r\n\u003Cp>\u003Csup>&#x2021;\u003C/sup>These authors have contributed equally to this work and share last authorship\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Materials and methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Data availability statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Author contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h17\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Conflict of interest\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Publisher&#x2019;s note\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h10\">Supplementary material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h11\">Abbreviations\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h12\">References\u003C/a>\u003C/li>\r\n\u003C/ul>\r\n",[801,806,812,815,821],{"name":802,"fileServerPackageEntryId":19,"fileServerId":803,"fileServerVersionNumber":786,"type":804},"EPUB.epub","1075806/epub",{"code":805,"name":805},"EPUB",{"name":807,"fileServerPackageEntryId":808,"fileServerId":809,"fileServerVersionNumber":786,"type":810},"fcvm-09-1075806.pdf","fcvm-09-1075806-r1/fcvm-09-1075806.pdf","1075806/pubmed-zip",{"code":811,"name":811},"PDF",{"name":807,"fileServerPackageEntryId":19,"fileServerId":813,"fileServerVersionNumber":786,"type":814},"1075806/publishers-proof/pdf",{"code":811,"name":811},{"name":816,"fileServerPackageEntryId":817,"fileServerId":809,"fileServerVersionNumber":786,"type":818},"fcvm-09-1075806.xml","fcvm-09-1075806-r1/fcvm-09-1075806.xml",{"code":819,"name":820},"NLM_XML","XML",{"name":822,"fileServerPackageEntryId":19,"fileServerId":823,"fileServerVersionNumber":390,"type":824},"Provisional PDF.pdf","1075806/provisional-pdf",{"code":811,"name":811},"v3",{"title":827,"link":828,"meta":832,"script":1065},"Frontiers | Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience",[829],{"rel":830,"href":831},"canonical","https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/full",[833,836,839,841,844,848,851,855,858,861,864,866,868,870,872,874,877,880,882,885,888,890,893,896,899,902,905,909,913,916,918,921,924,927,929,932,934,937,939,942,944,947,949,952,954,957,959,962,964,967,969,972,974,977,979,982,985,988,990,993,995,998,1000,1003,1006,1009,1011,1014,1016,1019,1021,1024,1026,1029,1031,1034,1037,1040,1042,1045,1047,1050,1052,1055,1057,1060,1062],{"hid":834,"property":834,"name":834,"content":835},"description","AbstractAimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy.  Treatment options in patients with advanced ATTR-CM are l...",{"hid":837,"property":837,"name":838,"content":827},"og:title","title",{"hid":840,"property":840,"name":834,"content":835},"og:description",{"hid":842,"name":842,"content":843},"keywords","Amyloid,transplant,Heart Failure,TTR = transthyretin,Outcome",{"hid":845,"property":845,"name":846,"content":847},"og:site_name","site_name","Frontiers",{"hid":849,"property":849,"name":383,"content":850},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1075806/fcvm-09-1075806-HTML-r1/image_m/fcvm-09-1075806-g001.jpg",{"hid":852,"property":852,"name":853,"content":854},"og:type","type","article",{"hid":856,"property":856,"name":857,"content":831},"og:url","url",{"hid":859,"name":859,"content":860},"twitter:card","summary_large_image",{"hid":862,"name":862,"content":863},"citation_volume","9",{"hid":865,"name":865,"content":116},"citation_journal_title",{"hid":867,"name":867,"content":847},"citation_publisher",{"hid":869,"name":869,"content":782},"citation_journal_abbrev",{"hid":871,"name":871,"content":783},"citation_issn",{"hid":873,"name":873,"content":533},"citation_doi",{"hid":875,"name":875,"content":876},"citation_firstpage","1075806",{"hid":878,"name":878,"content":879},"citation_language","English",{"hid":881,"name":881,"content":534},"citation_title",{"hid":883,"name":883,"content":884},"citation_keywords","Amyloid; transplant; Heart Failure; TTR = transthyretin; Outcome",{"hid":886,"name":886,"content":887},"citation_abstract","AbstractAimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy.  Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT).  Despite case series demonstrating comparable outcomes with CT between patients with ATTR-CM and non-amyloid cardiomyopathies, ATTR-CM is considered to be a contraindication to CT in some centres, partly due to a perceived risk of amyloid recurrence in the allograft.  We report long-term outcomes of CT in ATTR-CM at two tertiary centres.Methods and ResultsWe retrospectively evaluated ATTR-CM patients across two tertiary centres who underwent transplantation between 1990 and 2020.  Pre-transplantation characteristics were determined and outcomes were compared with a cohort of non-transplanted ATTR-CM patients.  Fourteen (12 male, 2 female) patients with ATTR-CM underwent CT including 11 with wild-type ATTR-CM and 3 with variant ATTR-CM (ATTRv).  Median age at CT was 62 years and median follow up post-CT was 66 months.  One, three, and five-year survival was 100%, 92% and 90%, respectively and the longest surviving patient was censored >19 years post CT.  No patients had recurrence of amyloid in the cardiac allograft.  Four patients died, including one with ATTRv-CM from complications of leptomeningeal amyloidosis.  Survival among the cohort of patients who underwent CT was significantly prolonged compared to UK patients with ATTR-CM generally (p\u003C0.001) including those diagnosed under age 65 years (p=0.008) or with early stage cardiomyopathy (p\u003C0.001). ConclusionCT is well-tolerated, restores functional capacity and improves prognosis in ATTR-CM.  The risk of amyloid recurrence in the cardiac allograft appears to be low.",{"hid":889,"name":889,"content":548},"citation_article_type",{"hid":891,"name":891,"content":892},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/pdf",{"hid":894,"name":894,"content":895},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1075806/xml",{"hid":897,"name":897,"content":898},"citation_fulltext_world_readable","yes",{"hid":900,"name":900,"content":901},"citation_online_date","2022/12/23",{"hid":903,"name":903,"content":904},"citation_publication_date","2023/01/19",{"hid":906,"name":907,"content":908},"citation_author_0","citation_author","Razvi, Yousuf ",{"hid":910,"name":911,"content":912},"citation_author_institution_0","citation_author_institution","Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, University College London, United Kingdom",{"hid":914,"name":907,"content":915},"citation_author_1","Porcari, Aldostefano ",{"hid":917,"name":911,"content":912},"citation_author_institution_1",{"hid":919,"name":907,"content":920},"citation_author_2","Di Nora, Concetta ",{"hid":922,"name":911,"content":923},"citation_author_institution_2","Department of Cardiothoracic Science, Azienda Sanitaria Universitaria Integrata di Udine, Italy",{"hid":925,"name":907,"content":926},"citation_author_3","Patel, Rishi K. ",{"hid":928,"name":911,"content":912},"citation_author_institution_3",{"hid":930,"name":907,"content":931},"citation_author_4","Ioannou, Adam ",{"hid":933,"name":911,"content":912},"citation_author_institution_4",{"hid":935,"name":907,"content":936},"citation_author_5","Rauf, Muhammad U. ",{"hid":938,"name":911,"content":912},"citation_author_institution_5",{"hid":940,"name":907,"content":941},"citation_author_6","Masi, Ambra ",{"hid":943,"name":911,"content":912},"citation_author_institution_6",{"hid":945,"name":907,"content":946},"citation_author_7","Law, Steven ",{"hid":948,"name":911,"content":912},"citation_author_institution_7",{"hid":950,"name":907,"content":951},"citation_author_8","Chacko, Liza ",{"hid":953,"name":911,"content":912},"citation_author_institution_8",{"hid":955,"name":907,"content":956},"citation_author_9","Rezk, Tamer ",{"hid":958,"name":911,"content":912},"citation_author_institution_9",{"hid":960,"name":907,"content":961},"citation_author_10","Ravichandran, Sriram ",{"hid":963,"name":911,"content":912},"citation_author_institution_10",{"hid":965,"name":907,"content":966},"citation_author_11","Gilbertson, Janet ",{"hid":968,"name":911,"content":912},"citation_author_institution_11",{"hid":970,"name":907,"content":971},"citation_author_12","Rowczenio, Dorota ",{"hid":973,"name":911,"content":912},"citation_author_institution_12",{"hid":975,"name":907,"content":976},"citation_author_13","Blakeney, Iona J. ",{"hid":978,"name":911,"content":912},"citation_author_institution_13",{"hid":980,"name":907,"content":981},"citation_author_14","Kaza, Nandita ",{"hid":983,"name":911,"content":984},"citation_author_institution_14","Imperial College London, United Kingdom",{"hid":986,"name":907,"content":987},"citation_author_15","Hutt, David F. ",{"hid":989,"name":911,"content":912},"citation_author_institution_15",{"hid":991,"name":907,"content":992},"citation_author_16","Lachmann, Helen ",{"hid":994,"name":911,"content":912},"citation_author_institution_16",{"hid":996,"name":907,"content":997},"citation_author_17","Wechalekar, Ashutosh ",{"hid":999,"name":911,"content":912},"citation_author_institution_17",{"hid":1001,"name":907,"content":1002},"citation_author_18","Moody, William ",{"hid":1004,"name":911,"content":1005},"citation_author_institution_18","Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom",{"hid":1007,"name":907,"content":1008},"citation_author_19","Lim, Sern ",{"hid":1010,"name":911,"content":1005},"citation_author_institution_19",{"hid":1012,"name":907,"content":1013},"citation_author_20","Chue, Colin ",{"hid":1015,"name":911,"content":1005},"citation_author_institution_20",{"hid":1017,"name":907,"content":1018},"citation_author_21","Whelan, Carol ",{"hid":1020,"name":911,"content":912},"citation_author_institution_21",{"hid":1022,"name":907,"content":1023},"citation_author_22","Venneri, Lucia ",{"hid":1025,"name":911,"content":912},"citation_author_institution_22",{"hid":1027,"name":907,"content":1028},"citation_author_23","Martinez-Naharro, Ana ",{"hid":1030,"name":911,"content":912},"citation_author_institution_23",{"hid":1032,"name":907,"content":1033},"citation_author_24","Merlo, Marco ",{"hid":1035,"name":911,"content":1036},"citation_author_institution_24","Cardiovascular Department, Centre for Diagnosis and Treatment of Cardiomyopathies, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Italy",{"hid":1038,"name":907,"content":1039},"citation_author_25","Sinagra, Gianfranco ",{"hid":1041,"name":911,"content":1036},"citation_author_institution_25",{"hid":1043,"name":907,"content":1044},"citation_author_26","Livi, Ugolino ",{"hid":1046,"name":911,"content":923},"citation_author_institution_26",{"hid":1048,"name":907,"content":1049},"citation_author_27","Hawkins, Philip ",{"hid":1051,"name":911,"content":912},"citation_author_institution_27",{"hid":1053,"name":907,"content":1054},"citation_author_28","Fontana, Marianna ",{"hid":1056,"name":911,"content":912},"citation_author_institution_28",{"hid":1058,"name":907,"content":1059},"citation_author_29","Gillmore, Julian D. ",{"hid":1061,"name":911,"content":912},"citation_author_institution_29",{"hid":1063,"name":1063,"content":1064},"dc.identifier","doi:10.3389/fcvm.2022.1075806",[1066,1069,1071,1073,1075],{"src":1067,"body":13,"type":1068,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":1070,"body":13,"type":1068,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":1072,"body":13,"type":1068,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":1074,"body":13,"type":1068,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fcvm.2022.1075806?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":1076,"body":13,"type":1068,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":1078,"articleHubArticlesList":1079,"canJournalHasArticleHub":375,"articleDoiList":1080},{},[],[],{"title":19,"image":-1,"breadcrumbs":1082,"linksCollection":1083,"metricsCollection":1085},[],{"total":387,"items":1084},[],{"total":387,"items":1086},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fcvm.2022.1075806?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>